

In The Matter Of:

*Eric Gwynne, etc. v.
University Hospitals of Cleveland, et al.*

*Arthur Zinn, M.D.
January 22, 2003*

*Mehler & Hagestrom
Court Reporters
1750 Midland Building
101 West Prospect Avenue
Cleveland, OH 44115
(216) 621-4984 FAX: (216) 621-0050*

*Original File 030122AZ.VI, 59 Pages
Min-U-Script® File ID: I689268261*

Word Index included with this Min-U-Script®

Page 1

[1] IN THE COURT OF COMMON PLEAS
[2] CUYAHOGA COUNTY, OHIO
[3] ERIC GWYNNE, ADMINISTRATOR
of the ESTATE OF EMILY
[4] GWYNNE, deceased,
[5] Plaintiff,
JUDGE GAUL
[6] -vs- CASE NO. 468327
[7] UNIVERSITY HOSPITALS OF
CLEVELAND, et al.,
[8] Defendants.
[9]
[10] Deposition of ARTHUR ZINN, M.D., taken as if
[11] upon cross-examination before Pamela S.
[12] Greenfield, a Registered Diplomat Reporter,
[13] Certified Realtime Reporter and Notary Public
[14] within and for the State of Ohio, at the offices
[15] of Reminger & Reminger, 1400 Midland Building,
[16] Cleveland, Ohio, at 11:00 a.m. on Wednesday,
[17] January 22, 2003, pursuant to notice and/or
[18] stipulations of counsel, on behalf of the
[19] Plaintiff in this cause.
[20]
[21] MEHLER & HAGESTROM
Court Reporters
[22]
CLEVELAND AKRON
[23] 1750 Midland Building 1015 Key Building
Cleveland, Ohio 44115 Akron, Ohio 44308
[24] 216.621.4984 330.535.7300
FAX 621.0050 FAX 535.0050
[25] 800.822.0650 800.562.7100

Page 2

[1] APPEARANCES:
[2] Donna Taylor-Kolis, Esq.
Friedman, Domiano & Smith
[3] 600 Standard Building
Cleveland, Ohio 44113
[4] (216) 621-0070,
[5] On behalf of the Plaintiff;
[6] George M. Moscarino, Esq.
Moscarino & Treu
[7] 630 Hanna Building
1422 Euclid Avenue
[8] Cleveland, Ohio 44115
(216) 621-1000,
[9]
On behalf of the Defendant
[0] University Hospitals of Cleveland;
[1] James L. Malone, Esq.
Marilena DiSilvio, Esq.
[2] Reminger & Reminger
1400 Midland Building
[3] 101 West Prospect Avenue
Cleveland, Ohio 44115
[4] (216) 687-1311,
[5] On behalf of the Defendants
Drs. Fanaroff, Zinn and Rodriguez.
[6]
[7]
[8]
[9]
[0]
[1]
[2]
[3]
[4]
[5]

	Page 3
[1] WITNESSINDEX	
[2]	
	PAGE
[3]	
[4] CROSS-EXAMINATION	
ARTHUR ZINN, M.D.	
[5] BY MS. KOLIS.....	4
[6]	
	EXHIBITINDEX
[7]	
[8] EXHIBIT	MARKED
[9]	
Plaintiffs' Exhibit A,	
[10] Zinn CV	9
[11] Plaintiffs' Exhibit B,	
three-page website printout.....	14
[12]	
Plaintiffs' Exhibit C,	
[13] five-page 11/7/00Wake Forest	
MolecularGenetic	
[14] Laboratory report.....	30
[15]	
[16]	
[17]	
[18]	
[19]	
[20]	
[21]	
[22]	
[23]	
[24]	
[25]	

[1] ARTHUR ZINN, M.D., of lawful age, called
[2] by the Plaintiff for the purpose of
[3] cross-examination, as provided by the Rules of
[4] Civil Procedure, being by me first duly sworn, as
[5] hereinafter certified, deposed and said as
[6] follows:
[7] CROSS-EXAMINATION OF ARTHUR ZINN, M.D.
[8] BY MS. KOLIS:
[9] Q: Doctor, just for identification purposes on the
[10] record, would you state your name and your
[11] professional address.
[12] A: My name is Arthur Brian Zinn and I work at
[13] University Hospitals of Cleveland and Case
[14] Western Reserve University.
[15] Q: Doctor, of course you know my name is Donna Kolis
[16] and I've been retained to represent the Estate of
[17] Emily Gwynne. My purpose today at this
[18] deposition is to find out what actual involvement
[19] you had in the care and treatment or consultation
[20] of this particular patient as well as to talk to
[21] you a little bit about LCHAD.
[22] Doctor, I know that you've given a deposition
[23] before. I'm correct in that assumption?
[24] A: I've given one deposition.
[25] Q: Was that the deposition that you gave, I believe

Page 5

[1] it was August of 2000, perhaps? Do you recall
[2] the deposition that you gave?
[3] A: I don't recall the date.
[4] Q: Do you know what case it was involving?
[5] MS. DiSILVIO: Objection. You
[6] may answer. You may answer.
[7] A: It was a case of Burdette.
[8] Q: That's the only one you recall giving a
[9] deposition in?
[10] A: You need to help me.
[11] Q: Sure.
[12] A: Is a deposition when I'm a defendant or I'm an
[13] expert witness?
[14] Q: Sometimes you could be a defendant, sometimes you
[15] could be an expert.
[16] A: Okay.
[17] Q: Sometimes you could be a subsequent treating
[18] physician.
[19] A: Thank you. So the only deposition I gave as a
[20] defendant was in Burdette.
[21] I've given other depositions, I think two as
[22] an expert witness.
[23] Q: All right. We'll get into that in just a second.
[24] Essentially, the ground rules are pretty
[25] simple. I ask questions. Hopefully you

Page 6

[1] understand the questions, understanding that I'm
[2] not a physician. If you answer a question, I'm
[3] going to assume you understood it.
[4] Therefore if there's any hesitancy in your
[5] own mind as to what information I'm seeking, you
[6] get to tell me that. Is that all right with you?
[7] A: Yes.
[8] Q: On occasion, Marilena may interpose an objection.
[9] You should wait until she and I resolve our
[10] differences before you answer the question. Do
[11] you understand that?
[12] A: Yes.
[13] Q: Okay. And so far you're doing wonderful. Each
[14] and every question has to be answered orally so
[15] that the court reporter can take down your
[16] answer. Is that acceptable to you?
[17] A: Yes.
[18] Q: Okay. Doctor, in anticipation of today's
[19] deposition, what materials did you review?
[20] A: The medical records.
[21] Q: Specifically what medical records did you review?
[22] A: The ones Ms. DiSilvio prepared and gave me.
[23] Q: Well, I don't know what she prepared and gave
[24] you, so you're going to have to tell us what
[25] medical records those are, facilities, dates,

Page 7

[1] whatever you have.
[2] **MS. DISILVIO:** Here. Let me help
[3] you out.
[4] **A:** I need some help.
[5] **Q:** If your attorney needs to help you during the
[6] deposition that's okay, too, as long as she
[7] doesn't answer for you.
[8] **A:** All I have to do is read what she prepared for
[9] me?
[10] **Q:** That's fine.
[11] **A:** Thank you. Index to medical records Volumes 1
[12] through 4 University Hospitals of Cleveland.
[13] **Q:** Have you seen —
[14] **A:** I'm not done yet.
[15] **Q:** Oh, I'm sorry. I thought you were done.
[16] **A:** Index to medical records, Volume 4 of 4 — oh,
[17] this is 1 of 4. 4 of 4. Volume 3 of 4.
[18] **MS. DISILVIO:** He also got Volume
[19] 4 but I didn't bring it because I didn't
[20] think you'd need it.
[21] **MR. MALONE:** Or 2 of 4.
[22] **MS. DISILVIO:** Whatever the other
[23] one is.
[24] **Q:** So you have three volumes of medical records,
[25] those include medical records only from

Page 8

[1] University Hospitals of Cleveland?
[2] **A:** Go back to Volume 1.
[3] **Q:** Okay. That's fine.
[4] **A:** Volume 1 is, A, University Hospitals of
[5] Cleveland — should I keep reading the page to
[6] you?
[7] **Q:** Yes, sir, so I know what you were able to review.
[8] **A:** Admission, labor and delivery, premature baby
[9] girl. Number 2, admission, postpartum
[10] respiratory distress syndrome, intraventricular
[11] hemorrhage, rule out metabolic disorder.
[12] I don't have Volume 2. I presume it's what
[13] came between Volume 3 and 4.
[14] **Q:** Right.
[15] **A:** I'm sorry.
[16] **Q:** That's okay.
[17] **A:** Volume 3 says A. University Hospitals of
[18] Cleveland, Number 2, admission, postpartum
[19] respiratory distress syndrome, intraventricular
[20] hemorrhage, rule out metabolic disorder. B,
[21] Dr. Fanaroff/Dr. Rodriguez office records. It
[22] goes on to say a little more. You want me to
[23] read everything on that or is that satisfactory?
[24] **Q:** Just as long as I know what records you reviewed,
[25] that's okay.

Page 9

[1] **A:** I don't know the detail you need. Number C is
[2] Aultman Hospital.
[3] Volume 4, D, E. James Witmer, M.D.
[4] E, Alliance Community Hospital.
[5] F, Children's Hospital Medical Center of
[6] Akron.
[7] G, death certificate.
[8] **Q:** Okay.
[9] **MS. DISILVIO:** Volume 2 for your
[10] purposes, Donna, is more of the UH chart
[11] that I just didn't bring with me today.
[12] **Q:** That's fine. I have a huge second one that I
[13] didn't bring with me today.
[14] All right. Doctor, we're going to mark your
[15] vitae which was given to me this morning,
[16] although I actually have seen one, Plaintiffs'
[17] Exhibit A.
[18]
[19] (Thereupon, Plaintiffs' Exhibit A,
[20] Zinn CV, was marked for purposes of
[21] identification.)
[22]
[23] **Q:** Basically, I don't think that we need to go
[24] through and recite what's contained in the vitae
[25] since it's self-explanatory but I just want to

Page 10

[1] make sure that I am correct about your
[2] certifications.
[3] You are board certified in clinical genetics,
[4] correct?
[5] **A:** Which page is that?
[6] **Q:** Page 2.
[7] **A:** Yes. Thank you.
[8] **Q:** And that was in 1982.
[9] **A:** I'm sorry. Could you repeat yourself?
[10] **Q:** Sure. You obtained your board in medical
[11] genetics?
[12] **A:** The first board was the American Board of Medical
[13] Examiners in 1981.
[14] **Q:** In terms of genetics, however, you obtained a
[15] board certification in 1982 in clinical genetics,
[16] right?
[17] **A:** Correct.
[18] **Q:** Then in 1996 you obtained an additional board in
[19] clinical bio, biochemical genetics; is that
[20] right?
[21] **A:** Right.
[22] **Q:** How long has that board been available, the one
[23] that you obtained in 1996?
[24] **A:** I think it was first available in '82.
[25] **Q:** Can you just sort of walk me through what made

Page 11

[1] you decide to get that board in 1996?

[2] **A:** My division chief asked me to do it for purposes

[3] of being able to accredit our unit as a training

[4] center for residents in medical genetics.

[5] **Q:** Were you seeking the accreditation through the

[6] AMA certification program or do you know which

[7] program?

[8] **A:** It, the American Board of Medical Genetics is one

[9] of the subboards of the American Board of Medical

[10] Specialties, so I don't, I may have the names

[11] slightly wrong but —

[12] **Q:** That's perfectly fine.

[13] **A:** — it's part of the AMA clinical boards.

[14] **Q:** And you have such a program in place now; is that

[15] correct?

[16] **A:** Such a program being?

[17] **Q:** The program that you were seeking this board

[18] certification in?

[19] **A:** Yes.

[20] **Q:** For residents?

[21] **A:** Yes.

[22] **Q:** And when did that program come into existence, if

[23] you know, doctor?

[24] **A:** It preceded 1996 but I don't know the date.

[25] **Q:** Before we move on to talking some more I guess

Page 12

[1] about your background, you indicated that you had

[2] served as an expert witness on two occasions; is

[3] that correct?

[4] **A:** Yes.

[5] **Q:** For whom did you serve as an expert witness?

[6] **MS. DISILVIO:** Objection. You

[7] may answer.

[8] **A:** I don't know the order. One case was for the

[9] United States Department of Justice. I believe

[10] that's what it is. It was for an alleged

[11] immunization reaction.

[12] **Q:** So you were a government witness in that matter?

[13] **MS. DISILVIO:** Objection. You

[14] may answer.

[15] **Q:** If you know.

[16] **A:** I don't know, actually.

[17] Let me think for a second. A U.S. attorney

[18] was the one who obtained my deposition.

[19] **Q:** And?

[20] **A:** And the second one was for a case involving a

[21] child at University Hospitals of Cleveland.

[22] **Q:** In that matter, did you offer expert testimony on

[23] behalf of the physicians involved in that matter?

[24] **A:** No. On behalf of the plaintiff.

[25] **Q:** Do you recall who the plaintiff's attorney was?

Page 13

[1] Was it Howard Mishkind?

[2] **A:** I truly don't remember.

[3] **Q:** That's all right. And you also indicated that

[4] you did give testimony in a case named Burdette.

[5] I gather you were a defendant in that matter?

[6] **A:** As I indicated —

[7] **MS. DISILVIO:** Objection.

[8] **A:** Yes.

[9] **Q:** Do you know what year that case was filed?

[10] **A:** No.

[11] **Q:** Do you know if that case was settled on your

[12] behalf?

[13] **MS. DISILVIO:** Objection.

[14] **A:** Which means?

[15] **Q:** You can answer.

[16] **MS. DISILVIO:** You can answer.

[17] **A:** The case was dismissed with prejudice.

[18] **Q:** When Emily was a patient in 1999, tell me how

[19] your department of genetics was organized at the

[20] hospital.

[21] **A:** I don't know how to answer that question.

[22] **Q:** Okay. Well, I guess we'll do a preempt. We'll

[23] make it a little easier.

[24] **A:** I'm not trying to be difficult.

[25] **Q:** I know that you're not.

Page 14

[1] **A:** I just don't know how to answer the question.

[2] **Q:** Okay. Your department has information which you

[3] post on the Internet, a web page. Are you

[4] familiar with that web page?

[5] **A:** I know they have one. I've never looked at it.

[6] **Q:** Okay. Well, the reason I asked you how your

[7] department was organized, the way that they break

[8] this out, and I'll mark it Plaintiffs' Exhibit B.

[9]

[10] (Thereupon, Plaintiffs' Exhibit B,

[11] three-page website printout, was marked for

[12] purposes of identification.)

[13]

[14] **Q:** I obtained this information off the Internet and

[15] the question I was asking you is it seems that

[16] there's a pretty accurate description, I'm

[17] hoping, of the services provided by the Center

[18] for Human Genetics. I don't know if you've had

[19] an opportunity to read it.

[20] **A:** I have not.

[21] **Q:** You are listed on the last page as your special

[22] interest, and I know that this is a typographical

[23] error, it says, "unborn errors of metabolism."

[24] I'm assuming it should say inborn errors of

[25] metabolism?

Page 15

[1] A: It should.
[2] Q: Is that your specialty within the group?
[3] A: That's one of them, yes.
[4] Q: Why don't you tell me, Dr. Zinn, we try to
[5] reference at depositions what you were doing at
[6] or around the time of the person's
[7] hospitalization. I don't really need to know
[8] what you do today but back in October/November of
[9] 1999, sort of describe for me what your
[10] responsibilities were within the group.
[11] A: I'm a clinical geneticist. I primarily see
[12] patients. I'm responsible for educating our
[13] residents as well as students who, or other
[14] residents who rotate through our service. I have
[15] some responsibility for academic performance as a
[16] member of the department of genetics.
[17] Q: Back in 1999 were you performing any research?
[18] A: I was not — can you define that for me?
[19] Q: Well, I assume research is research. Were you
[20] involved in any research projects on an ongoing
[21] basis at that time?
[22] A: No.
[23] Q: Are you now —
[24] A: I'm sorry. I may have been. I can't recall.
[25] Q: At this point in time, are you involved in any

Page 16

[1] research studies?
[2] MS. DISILVIO: Objection. You
[3] may answer. You may answer.
[4] A: No long-term research projects.
[5] Q: Doctor, what is LCHAD?
[6] A: It's an acronym.
[7] Q: And it's an acronym for what, if you want to —
[8] A: No.
[9] Q: Okay.
[10] A: It's an acronym for a long-chain
[11] 3-hydroxyacyl-CoA dehydrogenase.
[12] Q: When did LCHAD — and the acronym —
[13] A: Are we done with this?
[14] Q: — is in fact an inborn error of metabolism; is
[15] it not?
[16] A: Yes.
[17] Q: When did you become aware of the existence of
[18] LCHAD?
[19] A: I can't recall precisely.
[20] Q: Can you tell me if it was in the '70s?
[21] A: I think it was probably later than that.
[22] Q: The '80s?
[23] A: Probably.
[24] Q: In the '80s, I presume from looking at your
[25] curriculum vitae, you were a clinical geneticist

Page 17

[1] at that point in time, correct?
[2] A: Yes.
[3] Q: Prior to Emily Gwynne had you ever seen a child
[4] that had LCHAD?
[5] A: No.
[6] Q: How does one confirm a diagnosis of LCHAD?
[7] MS. DISILVIO: Now or then?
[8] Q: In October of 1999. October/November/December.
[9] A: By a combination of clinical studies and
[10] laboratory studies.
[11] Q: Tell me about the clinical studies first.
[12] A: You would look for evidence of hepatic
[13] dysfunction, cardiac dysfunction or skeletal
[14] muscle dysfunction.
[15] Q: And laboratory?
[16] A: You would do a combination of relatively routine
[17] laboratory studies.
[18] Q: Such as?
[19] A: A comprehensive chemistry panel.
[20] Q: Consisting of what?
[21] A: It's different things in different hospitals; but
[22] basically it's a blood sugar, a series of
[23] electrolytes.
[24] Q: What else?
[25] A: It depends somewhat on the clinical presentation.

Page 18

[1] Q: What about DNA testing?
[2] A: No.
[3] Q: Why?
[4] A: It wasn't clinically available.
[5] Q: Well, I guess we'll just deal with that issue.
[6] Is it your testimony, first of all, you were
[7] aware of the disorder, I think we've already
[8] established that, prior to 1999, correct?
[9] A: Yes.
[10] Q: And can I gather, and maybe I can't but we'll
[11] see, that this is something because of your
[12] interest in inborn errors of metabolism that you
[13] would have continually read the literature and
[14] made yourself aware of —
[15] MS. DISILVIO: Objection.
[16] Q: — in terms of advances in diagnoses and
[17] treatments?
[18] MS. DISILVIO: Objection. You
[19] may answer.
[20] A: I tend to read in my field of specialty, yes.
[21] Q: Is it your testimony under oath, doctor, that on
[22] October 28th, 29th, 30th, 31st of 1999 and
[23] beginning in the first couple of weeks of
[24] November, that there was no place that you could
[25] have sent a DNA sample and obtained a result on

Page 19

[1] Emily Gwynne?

[2] **A:** I didn't say that.[3] **Q:** Okay. Well, that's why I want to be sure about
[4] what you are saying.

[5] There were places where you could have sent

[6] Emily Gwynne's DNA sample. Is that a fair

[7] statement?

[8] **MS. DiSILVIO:** Objection. You

[9] may answer.

[10] **A:** Certainly there are places I could send her DNA.[11] **Q:** For analysis?[12] **A:** What kind of analysis?[13] **Q:** To determine whether or not she had LCHAD?[14] **A:** On a clinical basis? In a clinically useful

[15] manner? That's my question. That's why I'm

[16] having trouble answering you.

[17] **Q:** What facilities were you aware of in late 1999

[18] that would take a DNA sample and give you back a

[19] result as to whether or not there was an

[20] indication that a child had LCHAD?

[21] **A:** I was aware of no place that would do that on a

[22] clinical basis.

[23] **Q:** So it's your belief that there was no place in

[24] 1999 where you could send the DNA on a clinical

[25] basis?

Page 20

[1] **A:** That is correct.[2] **Q:** What about Washington University?[3] **A:** I was unaware that that was possible.[4] **Q:** Were you aware, doctor, that there were places

[5] that you could send the sample for testing that

[6] were on a research basis?

[7] **A:** Yes.[8] **Q:** What facilities were you aware of on a research

[9] basis?

[10] **A:** Washington University.[11] **Q:** What about Wake Forest?[12] **A:** I did not know that that was available.[13] **Q:** Do you know who Dr. Ibdah is?[14] **A:** I do not know him personally.[15] **Q:** Excuse me?[16] **A:** I do not know him personally.[17] **Q:** I wasn't asking if you knew him personally but

[18] that's inartful question asking on my part.

[19] Prior to Emily's admission to University

[20] Hospital, were you aware of Dr. Ibdah's research

[21] and writing in the area of LCHAD?

[22] **A:** He was a junior author on a paper by Dr. Strauss

[23] from Washington, yes.

[24] **Q:** Do you recall the title of that paper?[25] **A:** Not in precise words.

Page 21

[1] **Q:** Do you recall what the paper was about?[2] **A:** Yes.[3] **Q:** What was the paper about?[4] **A:** The paper was about the incidence of children

[5] with, the mothers of children who have LCHAD

[6] deficiency presenting with either acute fatty

[7] liver of pregnancy or HELLP syndrome. That's

[8] capital H-E-L-L-P.

[9] **Q:** Were you aware from reading that article that —

[10] I take it you read the article?

[11] **A:** I have.[12] **Q:** We establish that first.

[13] I had an opportunity last week to depose the

[14] resident who did the consultation with you in

[15] this matter, Do you recall that resident?

[16] **A:** Do you mean Derek?[17] **Q:** Yes.[18] **A:** Yes. I know Derek.[19] **Q:** And you still work with Derek, correct?[20] **A:** We still work together.[21] **Q:** Derek indicated in his testimony — I'm

[22] paraphrasing it since I don't have the transcript

[23] with me — that he was in possession of

[24] Dr. Ibdah's article at the time of Emily's

[25] consult.

Page 22

[1] Do you recall looking at the article at the
[2] time of Emily's consult?[3] **A:** Yes.[4] **Q:** Did you, because you looked at the article, did

[5] you become aware that Dr. Ibdah had in his

[6] facility at Wake Forest the ability to test DNA

[7] to look for the particular defect?

[8] **A:** I was more familiar with Dr. Strauss and he was

[9] the senior author and to my knowledge Dr. Strauss

[10] was, the work was done in Dr. Strauss' lab that I

[11] know about.

[12] **Q:** Would you agree with me that the presentation of

[13] Emily's mother with fatty liver disease in and of

[14] itself was an indication that the child should be

[15] worked up for LCHAD?

[16] **A:** Yes.[17] **Q:** Are you involved, doctor, at all in helping the

[18] State of Ohio make determinations as to which

[19] tests should be performed upon children at birth,

[20] newborn screening?

[21] **A:** I'm on the ad hoc newborn advisory committee.[22] **Q:** Did the State of Ohio this past June, maybe June

[23] 26th, 2002, recommend that LCHAD be tested for?

[24] **MS. DiSILVIO:** Objection.[25] **Q:** As an optional newborn screening test?

Page 23

[1] **MS. DISILVIO:** Objection. You
[2] may answer.
[3] **A:** Yes.
[4] **Q:** Do you know how that came about?
[5] **MS. DISILVIO:** Objection. You
[6] may answer.
[7] **MR. MOSCARINO:** Same objection.
[8] **Q:** Let me ask a better question.
[9] You told me you're on the ad hoc committee.
[10] I'm wondering if you had any input or involvement
[11] in helping the Department of Health determine
[12] that this was a good newborn screening test?
[13] **MR. MOSCARINO:** Objection to
[14] form.
[15] **MS. DISILVIO:** Objection. You
[16] may answer.
[17] **A:** I was present at several meetings of the State
[18] Newborn Advisory Board.
[19] **Q:** And at the meetings that you were present, did
[20] you participate in any conversations about
[21] screening for LCHAD?
[22] **MS. DISILVIO:** Objection. You
[23] may answer.
[24] **A:** I was not present at the meeting when the
[25] recommendation was made. I was present I believe

Page 24

[1] at a subsequent meeting where the implications of
[2] that were discussed.
[3] **Q:** Are there recorded minutes from these meetings?
[4] **MS. DISILVIO:** Objection. You
[5] may answer.
[6] **MR. MOSCARINO:** Can I just have a
[7] continuing objection to any kind of
[8] committee meetings that went on in 2002 or
[9] 2003 with regards to their application to
[10] the standard of care in '98?
[11] **MS. KOLIS:** I would agree that it
[12] doesn't apply to the standard of care. I'm
[13] simply trying to find out if there is a
[14] place where Dr. Zinn may have rendered some
[15] testimony.
[16] **MR. MOSCARINO:** I just don't want
[17] to interrupt anymore. I just made an
[18] objection to everything in 2002 and 2003.
[19] **MS. DISILVIO:** That's obviously
[20] my continuing objection, as well, and I'll
[21] just join in so I don't have to keep making
[22] that objection.
[23] **MR. MALONE:** And I'll ride on
[24] that cart.
[25] **A:** Having said that, folks?

Page 25

[1] **MS. DISILVIO:** You can answer.
[2] **A:** Thank you. There are minutes, I don't believe
[3] they are recorded minutes but I'm not in charge
[4] of the meeting and I may be inaccurate in that.
[5] **Q:** That's fine. I mean now that I know what
[6] committee you're on, there's mechanisms for me to
[7] try to obtain that information.
[8] Who is going to be performing the screening
[9] tests for the State for LCHAD?
[10] **MS. DISILVIO:** Objection.
[11] **Q:** If you know.
[12] **MS. DISILVIO:** You may answer.
[13] **A:** For the State of Ohio?
[14] **Q:** Yes.
[15] **A:** The screening is done through the Department of
[16] Health of the State of Ohio.
[17] **Q:** Do you know in what laboratory? Is there a
[18] laboratory that they've selected to —
[19] **A:** The Department of Health, the State of Ohio.
[20] **Q:** So they're going to have their own internal
[21] laboratory setting to screen for LCHAD?
[22] **A:** They're not screening for LCHAD per se. For
[23] their newborn screening.
[24] **Q:** In October of 1999, October, November and
[25] December of 1999, it's my understanding that the

Page 26

[1] lab at University Hospital was not able to
[2] perform a DNA test that would have indicated
[3] whether or not Emily had LCHAD. Is that a
[4] correct understanding?
[5] **MR. MALONE:** Can I have the
[6] question read back, please.
[7]
[8] (Thereupon, the requested portion of
[9] the record was read by the Notary.)
[10]
[11] **A:** It was not performing that test.
[12] If you ask me the able, the key to your
[13] question, they were potentially able to but they
[14] were not performing that test.
[15] **Q:** Potentially able meaning that they just hadn't
[16] set it up to test for LCHAD, not meaning they
[17] were incompetent. I wasn't implying that.
[18] **A:** Rut you said able.
[19] **Q:** But they were not doing that test, correct?
[20] **A:** That is correct.
[21] **Q:** In the past when you have had situations, not
[22] referring to LCHAD but other situations where
[23] there were inborn errors of metabolism, did you
[24] send those out to other laboratories when UH
[25] couldn't perform it?

[1] **MS. DISILVIO:** Objection. If you
[2] can answer that question. An objection as
[3] to relevance.

[4] **A:** Can you repeat the question for me or read it
[5] back, I guess.

[6] **Q:** Yes. She could read it back. That would be
[7] fine.

[8]
[9] (Thereupon, the requested portion of
[10] the record was read by the Notary.)
[11]

[12] **A:** I need to qualify your question, then.

[13] **Q:** That's fine.

[14] **A:** When there was, do you want me to answer for when
[15] there was a suspected case, which is the case for
[16] Emily, or when there are confirmed cases?

[17] **Q:** Suspected.

[18] **A:** I would send out — then the answer to that
[19] question is I would send out samples when there
[20] was a laboratory doing that test on a clinical
[21] basis.

[22] **Q:** So you're not restricted by the hospital from
[23] sending out samples when there are tests that can
[24] be performed that aren't being performed at UH;
[25] is that correct?

[1] **MS. DISILVIO:** Clinically
[2] available tests?

[3] **Q:** Or on a research basis.

[4] **MS. DISILVIO:** Objection. You
[5] may answer.

[6] **MR. MOSCARINO:** Object to the
[7] form.

[8] **A:** That's allowed to my clinical discretion.

[9] **Q:** That's, I just wanted to make sure that the
[10] hospital hadn't formulated some policy that
[11] prevented you from doing that if you so elected
[12] to do it based on your clinical judgment.

[13] **A:** The, I'll let it stand.

[14] **Q:** Sitting here today, do you know whether Emily
[15] Gwynne had LCHAD?

[16] **A:** From everything I've read, she does.

[17] **Q:** What is it —

[18] **A:** She did.

[19] **Q:** I'm sorry. What is it that you read that led you
[20] to that conclusion?

[21] **A:** My understanding is that she had mutational
[22] analysis performed. She subsequently had organic
[23] gas analysis and subsequently had acylcarnitine
[24] analysis, all three of which confirmed the
[25] diagnosis.

[1] And in addition she presented with clinical
[2] features of that disorder and at the time of
[3] autopsy had laboratory findings of that disease
[4] consistent with that disease.

[5] **Q:** I guess that I would like to in-depth probably
[6] evaluate the things that you evaluated that make
[7] you know that she did have LCHAD.

[8] First of all, were you contacted when Emily
[9] was admitted to Akron Children's Hospital?

[10] **A:** Yes.

[11] **Q:** Who contacted you?

[12] **A:** Dr. Gunay.

[13] **Q:** Is that someone that you knew prior to Emily's
[14] admission to Akron Children's?

[15] **A:** I need to correct. At the time that that was,
[16] Meral had married and changed her name. So I

[20] **A:** So if it's all right, with no disrespect, I'll
[21] call her Meral because otherwise I'll get it
[22] backwards. And Meral is M-E-R-A-L.

[23] **Q:** So she contacted you to let you know that Emily
[24] had been admitted to the hospital. Is that
[25] essentially it? That's how you became aware of

[1] it?

[2] **A:** Yes.

[3] **Q:** Did you talk with her after she received DNA
[4] analysis back on Emily?

[9] have been after she received her result.

[10] **Q:** Did she ever send you a copy of the DNA results
[11] from Wake Forest?

[12] **A:** Not to my memory.

[13] **MS. KOLIS:** What I'm going to do

[16]
[17] (Thereupon, Plaintiffs' Exhibit C,
[18] five-page 11/7/00 Wake Forest Molecular Genetic
[19] Laboratory report, was marked for purposes of
[20] identification.)

[22] **Q:** Doctor, what I'm handing you are laboratory
[23] results from Wake Forest University School of
[24] Medicine Department of Pediatrics Section of
[25] Medical Genetics and they are, there are some

Page 31

[1] findings for Emily Gwynne, Eric Gwynne and
[2] Kristie Gwynne and then there's some additional
[3] things we'll talk about afterwards?
[4] **MS. DISILVIO:** Why don't you take
[5] your time and go through those, doctor.
[6] **Q:** Yeah, I don't have a problem with that.
[7] **A:** Yes.
[8] **Q:** In doing a DNA mutation analysis looking for
[9] LCHAD, where is the defect found; do you know?
[10] **A:** I'm sorry. I was thinking about something. Tell
[11] me again.
[12] **Q:** Sure. Well, I could ask the question probably in
[13] a much simpler way. The first sheet of paper in
[14] the packet that I've given you are the results
[15] for Emily Gwynne?
[16] **A:** Yes.
[17] **Q:** Do those results indicate that Emily has LCHAD?
[18] **A:** It indicates that she's heterozygous for the
[19] common mutation consistent with the clinical
[20] disease of LCHAD. This testing tests for the
[21] genetic basis. She has the genetic basis
[22] consistent with that disease.
[23] **Q:** Have you ever seen, not Emily but prior to me
[24] showing you this, have you received reports like
[25] this from other laboratories having done testing

Page 32

[1] for the mutation?
[2] **A:** For this mutation?
[3] **Q:** Yes.
[4] **A:** I received — could you read the question back to
[5] me.
[6]
[7] (Thereupon, the requested portion of
[8] the record was read by the Notary.)
[9]
[10] **A:** Yes.
[11] **Q:** The LCHAD mutation, but I might be saying that
[12] incorrectly, just to clarify it.
[13] **A:** You're doing very well. You said it correctly.
[14] The answer is yes.
[15] **Q:** Okay. What other laboratories have you worked
[16] with?
[17] **MS. DISILVIO:** At what point in
[18] time?
[19] **Q:** Okay. Well, let me, that's a good preempt.
[20] Prior to October, November and December of
[21] 1999, had you ever sent any DNA out for analysis
[22] looking for the LCHAD mutation?
[23] **A:** Yes.
[24] **Q:** Where did you send them?
[25] **A:** Strauss.

Page 33

[1] **Q:** At Washington?
[2] **A:** Uh-huh.
[3] **Q:** What was the basis of your decision prior to
[4] Emily Gwynne in those other instances where you
[5] did send DNA to Strauss?
[6] **A:** It was a mother who presented with HELLP
[7] syndrome.
[8] **Q:** And was that the sole basis for that decision?
[9] **A:** And, yes. Yes.
[10] **Q:** When you consulted relative to Emily, and
[11] eventually we'll get to the consultation, what
[12] information did you have about her mother's
[13] pregnancy?
[14] **A:** That she had acute fatty liver of pregnancy
[15] confirmed by biopsy.
[16] **Q:** And as a result of that, Emily was delivered
[17] prematurely, correct?
[18] **A:** I believe so.
[19] **Q:** Well, I guess my question I'm asking you, if you
[20] can recall it today because I know it's been some
[21] time, did you have an opportunity to review
[22] Kristie Gwynne's chart at the time that you were
[23] consulting with Emily to see what the parameters
[24] of her pregnancy were and how it is that this
[25] child came to be delivered at 25 weeks?

Page 34

[1] **A:** I reviewed the basic information, yes.
[2] **Q:** Can you tell me today, doctor, why you elected
[3] not to send Emily's DNA for testing for LCHAD?
[4] **A:** Because the testing wasn't available on a
[5] clinical basis.
[6] **Q:** And you were uncomfortable sending it to a
[7] research-based test?
[8] **A:** First, the previous — yes.
[9] **Q:** Why?
[10] **A:** Okay. Three reasons, I think. One is that the
[11] federal government has actually tightened up
[12] considerably and it's no longer permissible, and
[13] our unit is being very careful, you cannot give
[14] research based data to patients. You cannot use
[15] it for clinical purposes so that in fact there
[16] are restrictions on that.
[17] Second, the testing had proved negative in
[18] the past, the relative minority of patients with
[19] acute fatty liver of pregnancy in fact had LCHAD
[20] deficiencies.
[21] Third, not knowing that that was the case, I
[22] thought that the primary way of establishing that
[23] diagnosis would be to use a broader based
[24] approach which is based on metabolite analysis
[25] and clinical exam.

Page 35

[1] Q: Just so I don't walk away saying I didn't ask
[2] that question, at what point did the federal
[3] government say that you couldn't use
[4] research-based information and share it with the
[5] patient?
[6] A: That was evolving over the last few years. I
[7] can't tell you exactly when.
[8] Q: That was not in fact the case in October of 1999,
[9] would you agree with that?
[10] A: That was not my understanding. But it was only
[11] one of four reasons.
[12] Q: Okay. But I just want to be real clear about
[13] that.
[14] A: Right. But there was, to skirt — it was not a
[15] clinical based test, which did affect my
[16] decision.
[17] Q: Why do you believe medically, not scriptly but
[18] why do you believe, doctor, that the battery of
[19] metabolic analysis that you were looking at
[20] proved, quote, unquote, negative during Emily's
[21] hospitalization at University Hospital?
[22] A: Because it was negative.
[23] Q: See, I know I was going to ask a lot of inartful
[24] questions.
[25] A: Ne. No. It's a perfectly fine one.

Page 36

[1] Q: We both agree that this child definitely had the
[2] LCHAD mutation?
[3] A: That is correct.
[4] Q: And clinically she manifested signs and symptoms
[5] consistent with that at a later point in her
[6] life, would you agree with that?
[7] A: Correct.
[8] MS. DiSILVIO: Subsequent to
[9] discharge.
[10] Q: Subsequent to discharge from University Hospital?
[11] A: Correct.
[12] Q: Why were those signs and symptoms not present
[13] during her hospitalization at University
[14] Hospital?
[15] A: I don't know the answer to that.
[16] Q: Well, we'll see if we can get some agreements
[17] which is very difficult for doctors to ever want
[18] to agree with you, but we could try.
[19] A: Excuse me?
[20] Q: In the interpretation of these tests, the
[21] clinical tests, and we're going to go back and
[22] sort of talk about what tests were run on Emily.
[23] Do you agree that those tests would essentially
[24] be negative if Emily was not in LCHAD crisis?
[25] MS. DiSILVIO: What tests?

Page 37

[1] Q: Well, that's what I'm going to ask him, what
[2] tests would we base it on?
[3] MS. DiSILVIO: Objection,
[4] MR. MALONE: I don't understand
[5] the question. I'm totally lost now.
[6] Q: All right. Here's what we'll do: Name each and
[7] every test that you recommended be performed on
[8] Emily to attempt to make a determination whether
[9] she was LCHAD, had LCHAD.
[10] MR. MALONE: I'm going to object.
[11] He's already testified that he looked at
[12] this patient globally. Clinically there
[13] were a number of labs.
[14] MS. KOLIS: Well, we're going to
[15] talk about the labs first and we're going
[16] to talk about clinical later.
[17] MR. MALONE: I understand. Let
[18] me make my objection, Donna, please.
[19] MS. KOLIS: That's fine.
[20] A: Would I, to answer your question, I'm going to go
[21] to the consult.
[22] Q: That's fine.
[23] A: On Page 4 of the consult dated 10/30/99, the
[24] first test was a plasma carnitine and
[25] acylcarnitine profile.

Page 38

[1] The second test was urine carnitine and
[2] acylcarnitine profile. The third test was urine
[3] organic acid analysis. The fourth test was
[4] mutational analysis of LCHAD gene; because of the
[5] elevated ammonia, ammonia analysis.
[6] An EKG.
[7] Q: Did you write the orders for these tests to be
[8] performed?
[9] A: No.
[10] Q: How do these tests, then, become performed if you
[11] don't write the orders for them?
[12] A: By providing the house staff with this
[13] recommendation and then the house staff or one of
[14] the neonatologists, whose care, who were
[15] providing the care for Emily.
[16] Q: Is that how it always occurs when you do an
[17] in-hospital consultation?
[18] A: If I'm not the primary providing physician, yes.
[19] Q: How do you receive the results of the laboratory
[20] tests that you are recommending?
[21] A: I usually receive them from the primary
[22] physician.
[23] Q: Do they call you with them? I mean, how does
[24] that work?
[25] A: Many times they call me.

Page 39

[1] Q: Do you have any notes, personal notes in a folder
[2] somewhere or otherwise or in the chart that
[3] indicate that you were made aware of any of the
[4] results of the tests that were performed on
[5] Emily?
[6] A: I have no personal notes to that effect.
[7] Q: What about in the chart?
[8] A: No.
[9] Q: Do you believe you were made aware of the results
[10] of these tests?
[11] A: I was made aware of the results of these tests,
[12] yes.
[13] Q: How do you believe you were made aware of them?
[14] A: Because I was.
[15] Q: I'm not trying to be difficult; but I don't —
[16] subsequent to the date of the consultation,
[17] doctor, did you record any further notes in the
[18] hospital chart of Emily Gwynne relative to your
[19] analysis of the results that came back?
[20] A: No.
[21] Q: So this is the sole note that you wrote — well,
[22] let me take that back.
[23] You countersigned a note written by Derek and
[24] I believe added something at the end of it; is
[25] that right?

Page 40

[1] MS. DISILVIO: Are you talking
[2] about the consult?
[3] Q: The consult. Let's start with that.
[4] MS. DISILVIO: Are you asking if
[5] that's his only note?
[6] Q: Right.
[7] A: Yes. I'm sorry. There's another addendum to
[8] Derek's short note which is a prelude to the
[9] complete consult.
[10] Q: And that's in the progress notes?
[11] A: Yes, ma'am.
[12] Q: But other than these two places, there are no
[13] further notes from you in the chart; is that
[14] correct?
[15] A: None that I could find.
[16] Q: Do you know what physician or physicians spoke
[17] with you about Emily after the consultation?
[18] A: I know I spoke with several people. I can't tell
[19] you everybody I spoke with.
[20] Q: If you can't tell me everyone, can you tell me
[21] anyone who you remember speaking to about her?
[22] A: I can do that.
[23] Q: Okay.
[24] A: I spoke with Eilene Stork. I spoke with
[25] Rodriguez, Riccardo Rodriguez and I remember

Page 41

[1] speaking with a Cynthia Bearer.
[2] Q: Did you ever speak with Dr. Fanaroff at or around
[3] the time of Emily's discharge from University
[4] Hospital?
[5] A: No.
[6] Q: Going back to your consultation, then, and you
[7] can, doctor, take as much time as you want, look
[8] anyplace in the chart, the plasma carnitine, and,
[9] I can't — the acylcarnitine — I'm getting good
[10] at pronouncing these words — profile that was
[11] performed. You know the results of that?
[12] A: Yes.
[13] Q: You can look at the results if you want to; but
[14] generally speaking, what did they indicate?
[15] A: Can I see them, please? Thank you.
[16] Q: I think that's the one.
[17] A: Yes.
[18] Q: Just for the record, could you indicate what
[19] you're looking at?
[20] A: I am looking at a quantitative acylcarnitine
[21] profile report on Emily, girl, Kristie. And the
[22] test date was, let's see, the date the sample was
[23] received was 02-November-99.
[24] Q: This particular test is performed in the
[25] Department of Veterans Affairs Medical Center,

Page 42

[1] correct?
[2] A: Physically the test is performed at the Veteran's
[3] Administration Hospital.
[4] Q: Is there something, based upon the inflection in
[5] your voice, is there —
[6] A: You said department. It's not the Department of
[7] Veterans Affairs, I thought. Maybe I misheard
[8] you. It's performed in a laboratory at the
[9] Veteran's Administration Medical Center.
[10] Q: At the clinical pharmacology lab there, correct?
[11] A: That's what it says, yes.
[12] Q: Is that correct?
[13] A: That is the designation for the laboratory.
[14] Q: Would you designate it some other way? Is there
[15] something you're trying to tell me?
[16] A: Yes.
[17] Q: Okay.
[18] A: I would designate it as — I'm trying to really
[19] answer your question as asked.
[20] Q: That's all right.
[21] A: They do call it department of. I never do.
[22] It's the VA, it's the VA branch of the Center
[23] for Inherited Disorders of Energy Metabolism.
[24] Q: So you wanted to really call them what they were
[25] versus what the stamp says across the top?

Page 43

[1] A: I'm sorry. Yes.
[2] Q: So you have those results and those are, I don't
[3] know what the name at the bottom says, that
[4] Dr. Hoppel, if that's not an L?
[5] A: That's Charles Hoppel.
[6] Q: Is it Charles Hoppel?
[7] A: Yes.
[8] Q: What do those results say to you about this
[9] child?
[10] A: The results say that the patient's total
[11] carnitine, free carnitine and total
[12] acylcarnitines are above the normal range. The
[13] acyl, the total acylcarnitine to free carnitine
[14] ratio is normal and the individual acylcarnitine
[15] profile is normal.
[16] Q: Now, this is one laboratory test that can aid and
[17] assist the physician in making a diagnosis of
[18] LCHAD, correct?
[19] A: Correct.
[20] Q: Going way back to the question I asked a little
[21] bit earlier, why was that test within the normal
[22] range given that we now know Emily definitely had
[23] LCHAD?
[24] A: The, it's a false negative.
[25] Q: Were you aware in October, November and December

Page 44

[1] of 1999 that it was possible to get a false
[2] negative using this particular test?
[3] A: The, to answer the question, how do you define
[4] possible? No. I'm —
[5] Q: That's okay. Were you aware that there was a
[6] false negative/false positive rate of error
[7] contained within the analysis of this test?
[8] A: Yes.
[9] Q: What did you believe the percentage was?
[10] A: I thought that percentage was small.
[11] Q: So in your opinion that is a false negative test
[12] if it —
[13] A: Speaking when?
[14] Q: As of —
[15] A: Speaking as of that date?
[16] Q: Correct.
[17] A: I thought this was a negative result.
[18] Q: Okay. I'm sorry. Are you —
[19] A: You asked me my time reference.
[20] Q: On that date?
[21] A: When I saw this result, I thought this was a
[22] negative result.
[23] Q: And now in retrospect you're saying that was in
[24] all likelihood a false negative result?
[25] A: Yes.

Page 45

[1] Q: To the best of your knowledge — I want to call
[2] you a metabolic geneticist. I probably shouldn't
[3] do that. As a geneticist?
[4] A: You may feel free to call me a metabolic
[5] geneticist.
[6] Q: To the best of your knowledge, in addition to
[7] potentially being a false negative result on that
[8] day, are you, do you believe that all children
[9] that have LCHAD will — okay. Let me withdraw
[10] the question. I know what I'm trying to ask and
[11] I have to ask it the right way.
[12] Going back to the other question that I had,
[13] have you reviewed any body of literature in your
[14] endeavor to understand LCHAD prior to Emily
[15] becoming a patient that indicates that this test
[16] may not give you a result that indicates LCHAD if
[17] the child has not yet gone into LCHAD crisis?
[18] MR. MALONE: I'm going to object
[19] because I think the question is almost
[20] incomprehensible; but if he understands it,
[21] that's not my client.
[22] A: Could you ask me the question again? I have
[23] trouble when there are objections, to make sure I
[24] focus, so could you ask me again?
[25] Q: Sure.

Page 46

[1] Could that result in fact be a correct
[2] result?
[3] A: It is a correct result.
[4] Q: And not —
[5] A: No, excuse me. It is a correct result.
[6] Q: And my question is prior to —
[7] A: To my knowledge, there's nothing to make me think
[8] this is not accurate.
[9] Q: Okay. So you think that test result is accurate?
[10] A: I think this test result is accurate.
[11] Q: Why would she have not shown positive signs of
[12] LCHAD on that test on that date?
[13] A: Because you can have false negative results.
[14] Q: Okay. We're going backwards. Is there any other
[15] reason other than a false negative result in this
[16] context that that report wouldn't have shown an
[17] indication for LCHAD?
[18] A: That the test is not accurate.
[19] Q: Okay. Hold on, though, to that piece of paper.
[20] We're going to go a different way.
[21] What happens to a child that has LCHAD
[22] doctor?
[23] MS. DiSILVIO: Clinically?
[24] Q: Yes.
[25] A: The clinical course is variable.

Page 47

[1] Q: In general, what is the concern for a child who
[2] has LCHAD?
[3] A: The concern is that you will have progressive
[4] hepatic and/or cardiac and/or skeletal muscle
[5] disease.
[6] Q: And how does that happen?
[7] A: I'm not sure I understand your question.
[8] Q: Sure. How is it that you get progressive
[9] hepatic, cardiac and skeletal disease if you have
[10] LCHAD?
[11] A: No one knows the precise mechanism.
[12] Q: Do you have an understanding of the mechanism
[13] even though you're saying no one knows the
[14] precise mechanism?
[15] A: My understanding of the mechanism is it's related
[16] to a relative energy deficiency for tissues that
[17] require fatty acid oxidation and/or potential
[18] toxic metabolites that accumulate secondary to
[19] the metabolic block and/or those metabolites
[20] impair other pathways.
[21] Q: And indeed it's implied in your answer the
[22] condition is progressive, correct?
[23] MS. DISILVIO: Objection. You
[24] may answer.
[25] A: I stated that it's a variable course. On average

Page 48

[1] it is not thought to be progressive.
[2] Q: Do you know the treatment for a child who has
[3] LCHAD once they're diagnosed?
[4] A: I know a treatment.
[5] Q: What is the treatment that you know?
[6] A: The treatment involves a combination of avoiding
[7] fasting, of frequent feedings and reduced fat
[8] in the diet and some individuals provide
[9] supplemental carnitine, but that's still debated.
[10] Q: I don't think I asked this question before and if
[11] I did, your attorney will graciously let me know.
[12] In anticipation of testifying here today, did
[13] you conduct a literature search of any sort
[14] regarding LCHAD?
[15] A: Not for myself, no.
[16] Q: Is the answer that you did not conduct a
[17] literature search?
[18] A: I, my attorney asked —
[19] MS. DISILVIO: I'm going to
[20] object to anything that he may have done
[21] for me.
[22] MS. KOLIS: That's fine.
[23] A: My attorney asked me —
[24] MS. DISILVIO: You don't have to
[25] answer that.

Page 49

[1] Q: You don't have to tell me that.
[2] A: I didn't know that.
[3] Q: All right. Doctor, do you have an opinion as to
[4] generally speaking the life expectancy of a child
[5] who has LCHAD if they are diagnosed?
[6] MS. DISILVIO: Objection. You
[7] may answer, if you know.
[8] MR. MALONE: I join the
[9] objection. I think you need a few more
[10] factors in there. Diagnosed and treated?
[11] MS. KOLIS: Right. Diagnosed and
[12] treated.
[13] MR. MALONE: What's the clinical
[14] situation, what's the age — there's a
[15] million variables to that question.
[16] MS. KOLIS: I'm sure there are
[17] but I'm going to ask the general question
[18] first.
[19] A: I would like a more specific, to answer your
[20] question, I would need more specifics.
[21] Q: Have you evaluated the studies that exist as to
[22] what the success rate is in treating the children
[23] that have been diagnosed with LCHAD strictly
[24] along the lines that you discussed before,
[25] focusing on the three, avoid fasting, frequent

Page 50

[1] feedings and reduction of the amount of fat in a
[2] diet?
[3] MS. DISILVIO: Objection. You
[4] may answer.
[5] A: I have evaluated various reports on the treatment
[6] of LCHAD deficiency.
[7] Q: Based upon your evaluation of those reports, do
[8] you have an opinion as to what the anticipated
[9] life expectancy can be for a child with an early
[10] diagnosis of LCHAD?
[11] MR. MALONE: Objection.
[12] A: How early is early?
[13] Q: Well, let's try someone who is diagnosed within
[14] the first four weeks of their life?
[15] MS. DISILVIO: Objection. You
[16] may answer.
[17] A: There are no prospective studies to answer that
[18] question.
[19] Q: What literature have you reviewed that indicates
[20] life expectancies to you in this arena?
[21] A: As of when?
[22] Q: As of — well, let's start first with as of
[23] October, 1999?
[24] A: I can't remember all the articles.
[25] Q: Suffice it to say based upon your testimony you

Page 51	Page 53
<p>[1] would have had to have read articles and relied</p> <p>[2] upon those for your understanding because you</p> <p>[3] hadn't conducted some independent study of your</p> <p>[4] own, correct?</p> <p>[5] A: Correct.</p> <p>[6] Q: And I think you already answered this but I just</p> <p>[7] want to be perfectly clear. Prior to Emily</p> <p>[8] Gwynne becoming a patient at University</p> <p>[9] Hospitals, had you seen, diagnosed or treated a</p> <p>[10] child with LCHAD?</p> <p>[11] A: No.</p> <p>[12] Q: Did you, prior to Emily's discharge from</p> <p>[13] University Hospitals, rule out LCHAD?</p> <p>[14] A: I'm sorry. Go ahead.</p> <p>[15] Q: See, your mind is working.</p> <p>[16] Did you, prior to Emily's discharge from</p> <p>[17] University Hospitals, rule out LCHAD?</p> <p>[18] A: To a clinically acceptable degree, yes.</p> <p>[19] Q: Define what you mean when you say to a clinically</p> <p>[20] acceptable degree.</p> <p>[21] A: I thought the, it was unlikely that she had LCHAD</p> <p>[22] deficiency.</p> <p>[23] Q: And the basis of your belief was what?</p> <p>[24] A: The a priori risk that she would have LCHAD</p> <p>[25] deficiency, the results of her clinical</p>	<p>[1] A: I'm sorry, It's the same — okay. It's a</p> <p>[2] quantitative acylcarnitine profile report on</p> <p>[3] Gwynne, Emily. Date received, 28-December-99.</p> <p>[4] Q: Okay. And you believe that you did see that</p> <p>[5] report?</p> <p>[6] A: Uh-huh.</p> <p>[7] Q: When do you think you saw that report?</p> <p>[8] MS. DISILVIO: Objection. Don't</p> <p>[9] guess.</p> <p>[10] Q: Do you know when you saw the report?</p> <p>[11] A: I just said I couldn't tell you exactly.</p> <p>[12] Q: Okay. Was it before or after Emily died?</p> <p>[13] MS. DISILVIO: Objection. If you</p> <p>[14] know.</p> <p>[15] A: I would say before.</p> <p>[16] Q: You would say that it was before? Are those</p> <p>[17] results different than the ones that occurred in</p> <p>[18] November?</p> <p>[19] MS. DISILVIO: Numerically</p> <p>[20] different?</p> <p>[21] A: Yes. Well, these are also urine. The other ones</p> <p>[22] you asked me about were plasma.</p> <p>[23] Q: I'm sorry. That's all right. You can talk about</p> <p>[24] those and I'll give you those, too.</p> <p>[25] A: Can I talk about the plasma first?</p>
Page 52	Page 54
<p>[1] evaluation by the neonatology service and the</p> <p>[2] results of the laboratory studies performed.</p> <p>[3] Q: To whom did you communicate that you believed</p> <p>[4] that she did not have LCHAD?</p> <p>[5] A: I had spoken with the neonatologist along the</p> <p>[6] way.</p> <p>[7] Q: But you didn't record, once again I'm just, you</p> <p>[8] know, there's no written report in some other</p> <p>[9] file?</p> <p>[10] A: That's correct.</p> <p>[11] Q: That you sent a report to anybody in the</p> <p>[12] department of neonatology, Dr. Fanaroff,</p> <p>[13] Dr. Rodriguez, Dr. Stork; is that right?</p> <p>[14] A: That's correct.</p> <p>[15] Q: Did you see the second set of quantitative</p> <p>[16] acylcarnitine profile report; do you know?</p> <p>[17] A: Yes.</p> <p>[18] Q: You did see it? Do you know when you saw it?</p> <p>[19] A: I can't tell you exactly.</p> <p>[20] Q: Let me just see if this refreshes your</p> <p>[21] recollection. I'm not going to even mark this.</p> <p>[22] Tell me what report I'm handing you.</p> <p>[23] A: Tell you?</p> <p>[24] Q: Just for the record so you can identify it, not</p> <p>[25] me.</p>	<p>[1] Q: Sure. You want to switch?</p> <p>[2] A: Yes, just to compare apples to apples.</p> <p>[3] Q: Okay.</p> <p>[4] A: So the answer to your question is — I'd need to</p> <p>[5] change that, then.</p> <p>[6] This is quantitative acylcarnitine profile.</p> <p>[7] It's on plasma on Emily Gwynne and the date</p> <p>[8] received is 27 December '99.</p> <p>[9] Q: Okay.</p> <p>[10] A: And the answer to your last question is yes, they</p> <p>[11] are different.</p> <p>[12] Q: In what regard are they different?</p> <p>[13] A: The total carnitine, the free carnitine are both</p> <p>[14] low and whereas the total acylcarnitines and the</p> <p>[15] acylcarnitine to free carnitine ratio is normal.</p> <p>[16] Q: What do the —</p> <p>[17] A: In addition, the —</p> <p>[18] Q: Go ahead.</p> <p>[19] A: The individual acylcarnitine profile, and that's,</p> <p>[20] which only has one species which is acetyl</p> <p>[21] carnitine, is low.</p> <p>[22] Q: What do the differences in those results mean to</p> <p>[23] you or what did they mean to you at the time when</p> <p>[24] you saw them?</p> <p>[25] A: It meant that Emily was, had a relatively low</p>

Page 55

[1] amount of total and free carnitine and, but the
[2] acyl to free ratio was normal suggesting she was
[3] not making any increased amounts of atypical or
[4] pathopneumonic acylcarnitines. In particular,
[5] the acyl, individual acylcarnitine profile at the
[6] bottom included only acetyl carnitine, did not
[7] include any of the individual acylcarnitines that
[8] are pathopneumonic for LCHAD deficiency or any
[9] other disorder of fatty acid, long-chain fatty
[10] acid oxidation, any other disorder of fatty acid
[11] oxidation, any organic acidemia or any other
[12] inborn error that might represent itself that
[13] might potentially be associated with LCHAD
[14] deficiencies.

[15] Q: I'm going to ask you the exact same question I
[16] asked you about the November labs.

[17] Why did that test not reveal the possibility
[18] of the existence of LCHAD?

[19] A: I don't know.

[20] Q: All right. I'll take it back. Thank you.

[21] I've already asked you about whether you
[22] wrote letters to the physicians in this case and
[23] the answer was no.

[24] Did you ever, first of all, do you recall
[E] talking with Eric Gwynne, Emily's father?

Page 56

[1] A: When?

[2] Q: At the time of your consultation in October?

[3] A: I don't have clear recollection of him.

[4] Q: Okay. I guess I asked a different question.

[5] Did you have a conversation with Mr. Gwynne
[6] regarding potentially what the concerns were
[7] about Emily?

[8] A: My memory is unclear about it.

[9] Q: Do you have a memory of any conversation ever
[10] with Eric Gwynne?

[11] A: To answer your question, I don't remember the
[12] conversation. I remember the fact that I had a
[13] conversation. I don't remember the conversation.

[14] Q: Did you ever contact any of the physicians at
[15] Aultman Hospital regarding your conclusions that
[16] Emily did not have LCHAD?

[17] A: No.

[18] Q: The plasma carnitine test that we're referring
[19] to, the second one?

[20] A: Yes.

[21] Q: That came back after Emily was discharged,
[22] correct?

[23] A: Right.

[24] Q: Do you think, not do you think.

[25] Do you recall having a conversation with

Page 57

[1] anyone at University Hospital, any of the
[2] attendings after you saw that result in January?

[3] A: No.

[4] Q: So the answer is no, you didn't have a
[5] conversation or you don't recall?

[6] A: You asked me did I recall.

[7] Q: Okay. Do you recall?

[8] A: No.

[9] Q: And the answer is no.

[10] And once again no notes reflecting that you
[11] received that test and then discussed this with
[12] anyone, correct?

[13] A: Correct.

[14] Q: Doctor, are you critical of anyone involved in
[15] the care and treatment of Emily Gwynne starting
[16] from the day she was born till the day she passed
[17] away?

[18] MR. MALONE: Objection.

[19] MS. DISILVIO: Same objection but
[20] you may answer.

[21] A: What do you mean by critical?

[24] Q: Do you feel that the action or inaction of any
[23] persons based upon the medical records that you
[24] reviewed caused or contributed to Emily's death?

[25] MS. DISILVIO: Objection. You

Page 58

[1] may answer.

[2] A: No, I'm not critical.

[3] Q: I have to think for a minute.

[4] A: I do, too.

[5] Q: Have you discussed this particular lawsuit with
[6] Drs. Rodriguez and Fanaroff?

[7] A: My only discussions were to say I couldn't talk
[8] about this with them.

[9] MS. KOLIS: Fair enough. All
[10] right, doctor, I don't have any further
[11] questions. Anyone else?

[12] MS. DISILVIO: Anyone else?

[13] MR. MALONE: No questions by
[14] Drs. Fanaroff and Rodriguez.

[15] MR. MOSCARINO: Off the record.

[16]

[17] (Thereupon, a discussion was had off
[18] the record.)

[19]

[20] MR. MOSCARINO: I have no
[21] questions.

[22] MS. DISILVIO: We'll read it.

[23] Thank you.

[24]

[25] ARTHUR ZINN, M.D.

Page 59

[1]
[2]
[3]
CERTIFICATE
[4]
[5] The State of Ohio,) SS:
County of Cuyahoga.)
[6]
[7]
I, Pamela S. Greenfield, a Notary Public
[8] within and for the State of Ohio, authorized to
administer oaths and to take and certify
[9] depositions, do hereby certify that the
above-named witness was by me, before the giving
[10] of their deposition, first duly sworn to testify
the truth, the whole truth, and nothing but the
[11] truth; that the deposition as above-set forth was
reduced to writing by me by means of stenotypy,
[12] and was later transcribed into typewriting under
my direction; that this is a true record of the
[13] testimony given by the witness; that said
deposition was taken at the aforementioned time,
[14] date and place, pursuant to notice or
stipulations of counsel; that I am not a relative
[15] or employee or attorney of any of the parties, or
a relative or employee of such attorney or
[16] financially interested in this action; that I am
not, nor is the court reporting firm with which I
[17] am affiliated, under a contract as defined in
Civil Rule 28(D).
[18]
IN WITNESS WHEREOF, I have hereunto set my
[19] hand and seal of office, at Cleveland, Ohio, this
____ day of _____, A.D. 20____.
[20]
[21]
[22] Pamela Greenfield, Notary Public, State of Ohio
1750 Midland Building, Cleveland, Ohio 44115
[23] My commission expires June 30, 2003
[24]
[25]

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

O	A			
02-November-99 41:23	ability 22:6	along 49:24; 52:5	36:21; 39:19, 22; 41:6;	cardiac 17:13; 47:4, 9
1	able 8:7; 11:3; 26:1, 12, 13, 15, 18	although 9:16	43:20; 45:12; 55:20; 56:21	care 4:19; 24:10, 12; 38:14, 15; 57:15
1 7:11, 17; 8:2, 4	above 43:12	always 38:16	background 12:1	careful 34:13
10/30/99 37:23	academic 15:15	AMA 11:6, 13	backwards 29:22; 46:14	carnitine 37:24; 38:1; 41:8; 43:11, 11, 13; 48:9; 54:13, 13, 15, 21; 55:1, 6; 56:18
11/7/00 30:18	acceptable 6:16; 51:18, 20	American 10:12; 11:8, 9	base 37:2	cart 24:24
1981 10:13	accredit 11:3	ammonia 38:5, 5	based 28:12; 34:14, 23, 24; 35:15; 42:4; 50:7, 25; 57:23	Case 4:13; 5:4, 7; 12:8, 20; 13:4, 9, 11, 17; 27:15, 15; 34:21; 35:8; 55:22
1982 10:8, 15	accreditation 11:5	amount 50:1; 55:1	basic 34:1	cases 27:16
1996 10:18, 23; 11:1, 24	accumulate 47:18	amounts 55:3	Basically 9:23; 17:22	caused 57:24
1999 13:18; 15:9, 17; 17:8; 18:8, 22; 19:17, 24; 25:24, 25; 32:21; 35:8; 44:1; 50:23	accurate 14:16; 46:8, 9, 10, 18	analysis 19:11, 12; 28:22, 23, 24; 30:4; 31:8; 32:21; 34:24; 35:19; 38:3, 4, 5; 39:19; 44:7	basis 15:21; 19:14, 22, 25; 20:6, 9; 27:21; 28:3; 31:21, 21; 33:3, 8; 34:5; 51:23	Center 9:5; 11:4; 14:17; 41:25; 42:9, 22
2	acid 38:3; 47:17; 55:9, 10, 10	and/or 47:4, 4, 17, 19	battery 35:18	Certainly 19:10
2 7:21; 8:9, 12, 18; 9:9; 10:6	acidemia 55:11	answered 6:14; 51:6	Bearer 41:1	certificate 9:7
2000 5:1	acronym 16:6, 7, 10, 12	anticipated 50:8	became 29:25	certification 10:15; 11:6, 18
2002 22:23; 24:8, 18	across 42:25	anticipation 6:18; 48:12	become 16:17; 22:5; 38:10	certifications 10:2
2003 24:9, 18	action 57:22	anymore 24:17	becoming 45:15; 51:8	certified 4:5; 10:3
25 33:25	actual 4:18	anyplace 41:8	beginning 18:23	change 54:5
26th 22:23	actually 9:16; 12:16; 34:11	apples 54:2, 2	belief 19:23; 51:23	changed 29:16, 18
27 54:8	acute 21:6; 33:14; 34:19	application 24:9	best 45:1, 6	charge 25:3
28-December-99 53:3	acyl 43:13; 55:2, 5	apply 24:12	better 23:8	Charles 43:5, 6
28th 18:22	acylcarnitine 28:23; 37:25; 38:2; 41:9, 20; 43:13, 14; 52:16; 53:2; 54:6, 15, 19; 55:5	approach 34:24	bio 10:19	chart 9:10; 33:22; 39:2, 7, 18; 40:13; 41:8
29th 18:22	acylcarnitines 43:12; 54:14; 55:4, 7	area 20:21	biochemical 10:19	chemistry 17:19
3	ad 22:21; 23:9	arena 50:20	biopsy 33:15	chief 11:2
3 7:17; 8:13, 17	ad 22:21; 23:9	around 15:6; 41:2	birth 22:19	child 12:21; 17:3; 19:20; 22:14; 33:25; 36:1; 43:9; 45:17; 46:21; 47:1; 48:2; 49:4; 50:9; 51:10
3-hydroxyacyl-CoA 16:11	added 39:24	ARTHUR 4:1, 7, 12; 58:25	bit 4:21; 43:21	children 21:4, 5; 22:19; 45:8; 49:22
30th 18:22	addendum 40:7	article 21:9, 10, 24; 22:1, 4	block 47:19	Children's 9:5; 29:9, 14
31st 18:22	addition 29:1; 45:6; 54:17	articles 50:24; 51:1	blood 17:22	Civil 4:4
4	additional 10:18; 31:2	assist 43:17	board 10:3, 10, 12, 12, 15, 18, 22; 11:1, 8, 9, 17; 23:18	clarify 32:12
4 7:12, 16, 16, 17, 17, 17, 19, 21; 8:13; 9:3; 37:23	address 4:11	associated 55:13	boards 11:13	clear 35:12; 51:7; 56:3
7	Administration 42:3, 9	assume 6:3; 15:19	body 45:13	Cleveland 4:13; 7:12; 8:1, 5, 18; 12:21
70s 16:20	Admission 8:8, 9, 18; 20:19; 29:14	assuming 14:24	born 57:16	client 45:21
8	admitted 29:9, 24	assumption 4:23	both 36:1; 54:13	clinical 10:3, 15, 19; 11:13; 15:11; 16:25; 17:9, 11, 25; 19:14, 22, 24; 27:20; 28:8, 12; 29:1; 31:19; 34:5, 15, 25; 35:15; 36:21; 37:16; 42:10; 46:25; 49:13; 51:25
80s 16:22, 24	advances 18:16	attempt 37:8	bottom 43:3; 55:6	clinically 18:4; 19:14; 28:1; 36:4; 37:12; 46:23; 51:18, 19
82 10:24	advisory 22:21; 23:18	attendings 57:2	branch 42:22	combination 17:9, 16; 48:6
9	Affairs 41:25; 42:7	attorney 7:5; 12:17, 25; 48:11, 18, 23	break 14:7	committee 22:21; 23:9; 24:8; 25:6
98 24:10	affect 35:15	atypical 55:3	Brian 4:12	common 31:19
99 54:8	afterwards 31:3	August 5:1	bring 7:19; 9:11, 13	communicate 52:3
	again 31:11; 45:22, 24; 52:7; 57:10	Aultman 9:2; 56:15	broader 34:23	Community 9:4
	age 4:1; 49:14	author 20:22; 22:9	Burdette 5:7, 20; 13:4	compare 54:2
	agree 22:12; 24:11; 35:9; 36:1, 6, 18, 23	autopsy 29:3	C	complete 40:9
	agreements 36:16	available 10:22, 24; 18:4; 20:12; 28:2; 34:4	C 9:1; 30:15, 17	comprehensive 17:19
	ahead 51:14; 54:18	average 47:25	call 29:17, 21; 38:23, 25; 42:21, 24; 45:1, 4	concern 47:1, 3
	aid 43:16	avoid 49:25	called 4:1	
	Akron 9:6; 29:9, 14	avoiding 48:6	came 8:13; 23:4; 33:25; 39:19; 56:21	
	alleged 12:10	aware 16:17; 18:7, 14; 19:17, 21; 20:4, 8, 20; 21:9; 22:5; 29:25; 39:3, 9, 11, 13; 43:25; 44:5	can 6:15; 10:25; 13:15, 16; 15:18; 16:20; 18:10; 24:6; 25:1; 26:5; 27:2, 4, 23; 33:20; 34:2; 36:16; 40:20, 22; 41:7, 13, 15; 43:16; 46:13; 50:9; 52:24; 53:23, 25	
	Alliance 9:4	away 35:1; 57:17	capital 21:8	
	allowed 28:8	Aygin 29:18		
	almost 45:19	B		
		B 8:20; 14:8, 10		
		baby 8:8		
		back 8:2; 15:8, 17; 19:18; 26:6; 27:5, 6; 30:4; 32:4;		

concerns 56:6 conclusion 28:20 conclusions 56:15 condition 47:22 conduct 48:13, 16 conducted 51:3 confirm 17:6 confirmed 27:16; 28:24; 33:15 considerably 34:12 consistent 29:4; 31:19, 22; 36:5 Consisting 17:20 consult 21:25; 22:2; 37:21, 23; 40:2, 3, 9 consultation 4:19; 21:14; 33:11; 38:17; 39:16; 40:17; 41:6; 56:2 consulted 33:10 consulting 33:23 contact 56:14 contacted 29:8, 11, 23 contained 9:24; 44:7 context 46:16 continually 18:13 continuing 24:7, 20 contributed 57:24 conversation 56:5, 9, 12, 13, 13, 25; 57:5 conversations 23:20 copy 30:10 correctly 32:13 countersigned 39:23 couple 18:23 course 4:15; 46:25; 47:25 court 6:15 crisis 36:24; 45:17 critical 57:14, 21; 58:2 cross-examination 4:3, 7 curriculum 16:25 CV 9:20 Cynthia 41:1	defect 22:7; 31:9 defendant 5:12, 14, 20; 13:5 deficiencies 34:20; 55:14 deficiency 21:6; 47:16; 50:6; 51:22, 25; 55:8 define 15:18; 44:3; 51:19 definitely 36:1; 43:22 degree 51:18, 20 dehydrogenase 16:11 delivered 33:16, 25 delivery 8:8 Department 12:9; 13:19; 14:2, 7; 15:16; 23:11; 25:15, 19; 30:24; 41:25; 42:6, 6, 21; 52:12 depends 17:25 depose 21:13 deposed 4:5 deposition 4:18, 22, 24, 25; 5:2, 9, 12, 19; 6:19; 7:6; 12:18 depositions 5:21; 15:5 Derek 21:16, 18, 19, 21; 39:23 Derek's 40:8 describe 15:9 description 14:16 designate 42:14, 18 designation 42:13 detail 9:1 determination 37:8 determinations 22:18 determine 19:13; 23:11 diagnosed 48:3; 49:5, 10, 11, 23; 50:13; 51:9 diagnoses 18:16 diagnosis 17:6; 28:25; 34:23; 43:17; 50:10 died 53:12 diet 48:8; 50:2 differences 6:10; 54:22 different 17:21, 21; 46:20; 53:17, 20; 54:11, 12; 56:4 difficult 13:24; 36:17; 39:15 discharge 36:9, 10; 41:3; 51:12, 16 discharged 56:21 discretion 28:8 discussed 24:2; 49:24; 57:11; 58:5 discussion 58:17 discussions 58:7 disease 22:13; 29:3, 4; 31:20, 22; 47:5, 9 DiSILVIO 5:5; 6:22; 7:2, 18, 22; 9:9; 12:6, 13; 13:7, 13, 16; 16:2; 17:7; 18:15, 18; 19:8; 22:24; 23:1, 5, 15, 22; 24:4, 19; 25:1, 10, 12; 27:1; 28:1, 4; 31:4;	32:17; 36:8, 25; 37:3; 40:1, 4; 46:23; 47:23; 48:19, 24; 49:6; 50:3, 15; 53:8, 13, 19; 57:19, 25; 58:12, 22 dismissed 13:17 disorder 8:11, 20; 18:7; 29:2; 55:9, 10 Disorders 42:23 disrespect 29:20 distress 8:10, 19 division 11:2 DNA 18:1, 25; 19:6, 10, 18, 24; 22:6; 26:2; 30:3, 10; 31:8; 32:21; 33:5; 34:3 Doctor 4:9, 15, 22; 6:18; 9:14; 11:23; 16:5; 18:21; 20:4; 22:17; 30:22; 31:5; 34:2; 35:18; 39:17; 41:7; 46:22; 49:3; 57:14; 58:10 doctors 36:17 done 7:14, 15; 16:13; 22:10; 25:15; 31:25; 48:20 Donna 4:15; 9:10; 37:18 down 6:15 Dr 8:21; 15:4; 20:13, 20, 22; 21:24; 22:5, 8, 9, 10; 24:14; 29:12; 41:2; 43:4; 52:12, 13, 13 Drs 58:6, 14 duly 4:4 during 7:5; 35:20; 36:13 dysfunction 17:13, 13, 14	Energy 42:23; 47:16 enough 58:9 Eric 31:1; 55:25; 56:10 error 14:23; 16:14; 44:6; 55:12 errors 14:23, 24; 18:12; 26:23 Essentially 5:24; 29:25; 36:23 establish 21:12 established 18:8 establishing 34:22 Estate 4:16 evaluate 29:6 evaluated 29:6; 49:21; 50:5 evaluation 50:7; 52:1 even 47:13; 52:21 eventually 33:11 everybody 40:19 everyone 40:20 evidence 17:12 evolving 35:6 exact 55:15 exactly 35:7; 52:19; 53:11 exam 34:25 Examiners 10:13 Excuse 20:15; 36:19; 46:5 Exhibit 9:17, 19; 14:8, 10; 30:15, 17 exist 49:21 existence 11:22; 16:17; 55:18 expectancies 50:20 expectancy 49:4; 50:9 expert 5:13, 15, 22; 12:2, 5, 22	features 29:2 federal 34:11; 35:2 feedings 48:7; 50:1 feel 45:4; 57:22 few 35:6; 49:9 field 18:20 file 52:9 filed 13:9 find 4:18; 24:13; 40:15 findings 29:3; 31:1 fine 7:10; 8:3; 9:12; 11:12; 25:5; 27:7, 13; 35:25; 37:19, 22; 48:22 first 4:4; 10:12, 24; 17:11; 18:6, 23; 21:12; 29:8; 31:13; 34:8; 37:15, 24; 49:18; 50:14, 22; 53:25; 55:24 five-page 30:18 focus 45:24 focusing 49:25 folder 39:1 folks 24:25 follows 4:6 Forest 20:11; 22:6; 30:11, 18, 23 form 23:14; 28:7 formulated 28:10 found 31:9 four 35:11; 50:14 fourth 38:3 free 43:11, 13; 45:4; 54:13, 15; 55:1, 2 frequent 48:7; 49:25 further 39:17; 40:13; 58:10	
D		E	E 9:3, 4 earlier 43:21 early 50:9, 12, 12 easier 13:23 educating 15:12 effect 39:6 Eilene 40:24 either 21:6 EKG 38:6 elected 28:11; 34:2 electrolytes 17:23 elevated 38:5 else 17:24; 58:11, 12 Emily 4:17; 13:18; 17:3; 19:1, 6; 26:3; 27:16; 28:14; 29:8, 23; 30:4; 31:1, 15, 17, 23; 33:4, 10, 16, 23; 36:22, 24; 37:8; 38:15; 39:5, 18; 40:17; 41:21; 43:22; 45:14; 51:7; 53:3, 12; 54:7, 25; 56:7, 16, 21; 57:15 Emily's 20:19; 21:24; 22:2, 13; 29:13; 34:3; 35:20; 41:3; 51:12, 16; 55:25; 57:24 end 39:24 endeavor 45:14	F	G
			= 9:5 'acilities 6:25; 19:17; 20:8 'acility 22:6 'act 16:14; 34:15, 19; 35:8; 46:1; 56:12 'actors 49:10 'air 19:6; 58:9 'also 43:24; 44:1, 6, 11, 24; 45:7; 46:13, 15 'amiliar 14:4; 22:8 'anaroff 41:2; 52:12; 58:6, 14 'anaroff/Dr 8:21 ar 6:13 asting 48:7; 49:25 at 48:7; 50:1 ather 55:25 atty 21:6; 22:13; 33:14; 34:19; 47:17; 55:9, 9, 10		

graciously 48:11 ground 5:24 group 15:2, 10 guess 11:25; 13:22; 18:5; 27:5; 29:5; 33:19; 53:9; 56:4 Gunay 29:12, 17 Gwynne 4:17; 17:3; 19:1; 28:15; 31:1, 1, 2, 15; 33:4; 39:18; 51:8; 53:3; 54:7; 55:25; 56:5, 10; 57:15 Gwynne's 19:6; 33:22	implying 26:17 in-depth 29:5 in-hospital 38:17 inaccurate 25:4 inaction 57:22 inartful 20:18; 35:23 inborn 14:24; 16:14; 18:12; 26:23; 55:12 incidence 21:4 include 7:25; 55:7 included 55:6 incompetent 26:17 incomprehensible 45:20 incorrectly 32:12 increased 55:3 indeed 47:21 independent 51:3 Index 7:11, 16 indicate 31:17; 39:3; 41:14, 18 indicated 12:1; 13:3, 6; 21:21; 26:2 indicates 31:18; 45:15, 16; 50:19 indication 19:20; 22:14; 46:17 individual 43:14; 54:19; 55:5, 7 individuals 48:8 inflection 42:4 information 6:5; 14:2, 14; 25:7; 33:12; 34:1; 35:4 Inherited 42:23 input 23:10 instances 33:4 interest 14:22; 18:12 Internal 25:20 Internet 14:3, 14 interpose 6:8 interpretation 36:20 interrupt 24:17 into 5:23; 11:22; 45:17 intraventricular 8:10, 19 involved 12:23; 15:20, 15; 22:17; 57:14 involvement 4:18; 23:10 involves 48:6 involving 5:4; 12:20 Issue 18:5	K keep 8:5; 24:21 key 26:12 kind 19:12; 24:7 knew 20:17; 29:13, 17 knowing 34:21 knowledge 22:9; 45:1, 6; 46:7 knows 47:11, 13 KOLIS 4:8, 15; 24:11; 30:13; 37:14, 19; 48:22; 49:11, 16; 58:9 Kristie 31:2; 33:22; 41:21	looked 14:5; 22:4; 37:11 looking 16:24; 22:1; 31:8 32:22; 35:19; 41:19, 20 lost 37:5 lot 35:23 low 54:14, 21, 25	metabolites 47:18, 19 might 32:11; 55:12, 13 million 49:15 mind 6:5; 51:15 minority 34:18 minute 58:3 minutes 24:3; 25:2, 3 misheard 42:7 Mishkind 13:1 Molecular 30:18 more 8:22; 9:10; 11:25; 22:8; 49:9, 19, 20 morning 9:15 MOSCARINO 23:7, 13; 24:6, 16; 28:6; 58:15, 20 mother 22:13; 33:6 mother's 33:12 mothers 21:5 move 11:25 much 31:13; 41:7 muscle 17:14; 47:4 must 30:8 mutation 31:8, 19; 32:1, 2, 11, 22; 36:2 mutational 28:21; 38:4 myself 48:15
H H-E-L-L-P 21:8 handing 30:22; 52:22 happen 47:6 happens 46:21 Health 23:11; 25:16, 19 HELLP 21:7; 33:6 help 5:10; 7:2, 4, 5 helping 22:17; 23:11 hemorrhage 8:11, 20 hepatic 17:12; 47:4, 9 Here's 37:6 hereinafter 4:5 hesitancy 6:4 heterozygous 31:18 hoc 22:21; 23:9 Hold 46:19 Hopefully 5:25 hoping 14:17 Hoppel 43:4, 5, 6 Hospital 9:2, 4, 5; 13:20; 20:20; 26:1; 27:22; 28:10; 29:9, 24; 35:21; 36:10, 14; 39:18; 41:4; 42:3; 56:15; 57:1 hospitalization 15:7; 35:21; 36:13 Hospitals 4:13; 7:12; 8:1, 4, 17; 12:21; 17:21; 51:9, 13, 17 house 38:12, 13 Howard 13:1 huge 9:12 Human 14:18 hyphenated 29:19	I Ibdah 20:13; 22:5 Ibdah's 20:20; 21:24 identification 4:9; 9:21; 14:12; 30:20 identify 52:24 immunization 12:11 impair 47:20 implication 30:8 implications 24:1 implied 47:21	L L 43:4 lab 22:10; 26:1; 42:10 labor 8:8 laboratories 26:24; 31:25; 32:15 laboratory 17:10, 15, 17; 25:17, 18, 21; 27:20; 29:3; 30:19, 22; 38:19; 42:8, 13; 43:16; 52:2 labs 37:13, 15; 55:16 last 14:21; 21:13; 35:6; 54:10 late 19:17 later 16:21; 36:5; 37:16 lawful 4:1 awsuit 58:5 LCHAD 4:21; 16:5, 12, 18; 17:4, 6; 19:13, 20; 20:21; 21:5; 22:15, 23; 23:21; 25:9, 21, 22; 26:3, 16, 22; 28:15; 29:7; 31:9, 17, 20; 32:11, 22; 34:3, 19; 36:2, 24; 37:9, 9; 38:4; 43:18, 23; 45:9, 14, 16, 17; 46:12, 17, 21; 47:2, 10; 48:3, 14; 49:5, 23; 50:6, 10; 51:10, 13, 17, 21, 24; 52:4; 55:8, 13, 18; 56:16 led 28:19 letters 55:22 life 36:6; 49:4; 50:9, 14, 20 likelihood 44:24 lines 49:24 listed 14:21 literature 18:13; 45:13; 48:13, 17; 50:19 little 4:21; 8:22; 13:23; 13:20 liver 21:7; 22:13; 33:14; 14:19 long 7:6; 8:24; 10:22 long-chain 16:10; 55:9 long-term 16:4 longer 34:12 look 17:12; 22:7; 41:7, 13	M M-E-R-A-L 29:22 M.D 4:1, 7; 9:3; 58:25 ma'am 40:11 making 24:21; 43:17; 55:3 MALONE 7:21; 24:23; 26:5; 37:4, 10, 17; 45:18; 49:8, 13; 50:11; 57:18; 58:13 manifested 36:4 manner 19:15 Many 38:25 Marilena 6:8 mark 9:14; 14:8; 30:14; 52:21 marked 9:20; 14:11; 30:19 married 29:16 materials 6:19 natter 12:12, 22, 23; 13:5; 21:15 nay 5:6, 6; 6:8; 11:10; 12:7, 14; 15:24; 16:3, 3; 18:19; 19:9; 23:2, 6, 16, 23; 24:5, 14; 25:4, 12; 28:5; 45:4, 16; 47:24; 48:20; 49:7; 50:4, 16; 57:20; 58:1 maybe 18:10; 22:22; 42:7 mean 21:16; 25:5; 38:23; 51:19; 54:22, 23; 57:21 meaning 26:15, 16 means 13:14 neant 54:25 mechanism 47:11, 12, 4, 15 mechanisms 25:6 medical 6:20, 21, 25; 11, 16, 24, 25; 9:5; 10:10, 12; 11:4, 8, 9; 10:25; 41:25; 42:9; 57:23 medically 35:17 Medicine 30:24 meeting 23:24; 24:1; 25:4 meetings 23:17, 19; 14:3, 8 member 15:16 memory 30:12; 56:8, 9 Menial 29:16, 17, 21, 22 metabolic 8:11, 20; 5:19; 45:2, 4; 47:19 metabolism 14:23, 25; 6:14; 18:12; 26:23; 42:23 metabolite 34:24	N name 4:10, 12, 15; 29:16; 37:6; 43:3 named 13:4 names 11:10 need 5:10; 7:4, 20; 9:1, 23; 15:7; 27:12; 29:15; 49:9, 20; 54:4 needs 7:5 negative 34:17; 35:20, 22; 36:24; 43:24; 44:2, 11, 17, 22, 24; 45:7; 46:13, 15 negative/false 44:6 neonatologist 52:5 neonatologists 38:14 neonatology 52:1, 12 newborn 22:20, 21, 25; 23:12, 18; 25:23 None 40:15 Normal 43:12, 14, 15, 21; 14:15; 55:2 Notary 26:9; 27:10; 32:8 note 39:21, 23; 40:5, 8 notes 39:1, 1, 6, 17; 10:10, 13; 57:10 November 18:24; 25:24; 12:20; 43:25; 53:18; 55:16 Number 8:9, 18; 9:1; 17:13 Numerically 53:19

O	P		Q	
<p>oath 18:21 Object 28:6; 37:10; 45:18; 48:20 Objection 5:5; 6:8; 12:6; 13:13; 7:13; 16:2; 18:15; 18:19; 8:22; 24:23; 1:5, 7, 13, 15, 22; 24:4, 7, 18, 20, 22; 25:10; 27:1, 2; 28:4; 37:3, 18; 47:23; 49:6, 9; 50:3, 11, 15; 53:8, 13; 57:18, 19, 25 objections 45:23 obtain 25:7 obtained 10:10, 14, 18, 23; 12:18; 14:14; 18:25 obviously 24:19 occasion 6:8 occasions 12:2 occurred 53:17 occurs 38:16 October 17:8; 18:22; 25:24, 24; 32:20; 35:8; 43:25; 50:23; 56:2 October/November 15:8 October/November-December 17:8 off 14:14; 58:15, 17 offer 12:22 office 8:21 Ohio 22:18, 22; 25:13, 16, 19 once 48:3; 52:7; 57:10 one 4:24; 5:8; 7:23; 9:12, 16; 10:22; 11:8; 12:8, 18, 20; 14:5; 15:3; 17:6; 34:10; 35:11, 25; 38:13; 41:16; 43:16; 47:11, 13; 54:20; 56:19 ones 6:22; 53:17, 21 ongoing 15:20 only 5:8, 19; 7:25; 35:10; 40:5; 54:20; 55:6; 58:7 opinion 44:11; 49:3; 50:8 opportunity 14:19; 21:13; 33:21 optional 22:25 orally 6:14 order 12:8 orders 38:7, 11 organic 28:22; 38:3; 55:11 organized 13:19; 14:7 otherwise 29:21; 39:2 out 4:18; 7:3; 8:11, 20; 14:8; 24:13; 26:24; 27:18, 19, 23; 32:21; 51:13, 17 over 35:6 own 6:5; 25:20; 51:4 oxidation 47:17; 55:10, 11</p>	<p>packet 31:14 page 8:5; 10:5, 6; 14:3, 4, 21; 37:23 panel 17:19 paper 20:22, 24; 21:1, 3, 4; 31:13; 46:19 parameters 33:23 paraphrasing 21:22 part 11:13; 20:18 participate 23:20 particular 4:20; 22:7; 41:24; 44:2; 55:4; 58:5 passed 57:16 past 22:22; 26:21; 34:18 pathopneumonic 55:4, 8 pathways 47:20 patient 4:20; 13:18; 35:5; 37:12; 45:15; 51:8 patient's 43:10 patients 15:12; 34:14, 18 Pediatrics 30:24 people 40:18 per 25:22 percentage 44:9, 10 perfectly 11:12; 35:25; 51:7 perform 26:2, 25 performance 15:15 performed 22:19; 27:24, 24; 28:22; 37:7; 38:8, 10; 39:4; 41:11, 24; 42:2, 8; 52:2 performing 15:17; 25:8; 26:11, 14 perhaps 5:1 permissible 34:12 person's 15:6 personal 39:1, 6 personally 20:14, 16, 17 persons 57:23 pharmacology 42:10 Physically 42:2 physician 5:18; 6:2; 38:18, 22; 40:16; 43:17 physicians 12:23; 40:16; 55:22; 56:14 piece 46:19 place 11:14; 18:24; 19:21, 23; 24:14 places 19:5, 10; 20:4; 40:12 Plaintiff 4:2; 12:24 plaintiff's 12:25 Plaintiffs 9:16, 19; 14:8, 10; 30:14, 17 plasma 37:24; 41:8; 53:22, 25; 54:7; 56:18 please 26:6; 37:18; 41:15 Joint 15:25; 17:1; 32:17;</p>	<p>35:2; 36:5 policy 28:10 portion 26:8; 27:9; 32:7 positive 44:6; 46:11 possession 21:23 possibility 55:17 possible 20:3; 44:1, 4 post 14:3 postpartum 8:9, 18 potential 47:17 potentially 26:13, 15; 45:7; 55:13; 56:6 preceded 11:24 precise 20:25; 47:11, 14 precisely 16:19 preempt 13:22; 32:19 pregnancy 21:7; 33:13, 14, 24; 34:19 prejudice 13:17 prelude 40:8 premature 8:8 prematurely 33:17 prepared 6:22, 23; 7:8 present 23:17, 19, 24, 25; 36:12 presentation 17:25; 22:12 presented 29:1; 33:6 presenting 21:6 presume 8:12; 16:24 pretty 5:24; 14:16 prevented 28:11 previous 34:8 primarily 15:11 primary 34:22; 38:18, 21 printout 14:11 Prior 17:3; 18:8; 20:19; 29:13; 31:23; 32:20; 33:3; 45:14; 46:6; 51:7, 12, 16 priori 51:24 probably 16:21, 23; 29:5; 31:12; 45:2 problem 31:6 Procedure 4:4 professional 4:11 profile 37:25; 38:2; 41:10, 21; 43:15; 52:16; 53:2; 54:6, 19; 55:5 program 11:6, 7, 14, 16, 17, 22 progress 40:10 progressive 47:3, 8, 22; 48:1 projects 15:20; 16:4 pronouncing 41:10 prospective 50:17 proved 34:17; 35:20 provide 48:8 provided 4:3; 14:17 providing 38:12, 15, 18 purpose 4:2, 17 purposes 4:9; 9:10, 20;</p>	<p>11:2; 14:12; 30:19; 34:15 qualify 27:12 quantitative 41:20; 52:15; 53:2; 54:6 quote 35:20 range 43:12, 22 rate 44:6; 49:22 ratio 43:14; 54:15; 55:2 reaction 12:11 read 7:8; 8:23; 14:19; 18:13, 20; 21:10; 26:6, 9; 27:4, 6, 10; 28:16, 19; 32:4, 8; 51:1; 58:22 reading 8:5; 21:9 real 35:12 really 15:7; 42:18, 24 reason 14:6; 46:15 reasons 34:10; 35:11 recall 5:1, 3, 8; 12:25; 15:24; 16:19; 20:24; 21:1, 15; 22:1; 33:20; 55:24; 56:25; 57:5, 6, 7 receive 38:19, 21 received 30:3, 9; 31:24; 32:4; 41:23; 53:3; 54:8; 57:11 recite 9:24 recollection 52:21; 56:3 recommend 22:23 recommendation 23:25; 38:13 recommended 37:7 recommending 38:20 record 4:10; 26:9; 27:10; 32:8; 39:17; 41:18; 52:7, 24; 58:15, 18 recorded 24:3; 25:3 records 6:20, 21, 25; 7:11, 16, 24, 25; 8:21, 24; 57:23 reduced 48:7 *education 50:1 reference 15:5; 44:19 referring 26:22; 56:18 reflecting 57:10 refreshes 52:20 regard 54:12 regarding 48:14; 56:6, 5 regards 24:9 related 47:15 relative 33:10; 34:18; 49:18; 47:16 relatively 17:16; 54:25 relevance 27:3 relied 51:1</p>	<p>remember 13:2; 30:5, 5; 40:21, 25; 50:24; 56:11, 12, 13 rendered 24:14 repeat 10:9; 27:4 report 30:19; 41:21; 46:16; 52:8, 11, 16, 22; 53:2, 5, 7, 10 reporter 6:15 reports 31:24; 50:5, 7 represent 4:16; 55:12 requested 26:8; 27:9; 32:7 require 47:17 research 15:17, 19, 19, 20; 16:1, 4; 20:6, 8, 20; 28:3; 34:14 research-based 34:7; 35:4 Reserve 4:14 resident 21:14, 15 residents 11:4, 20; 15:13, 14 resolve 6:9 respiratory 8:10, 19 responsibilities 15:10 responsibility 15:15 responsible 15:12 restricted 27:22 restrictions 34:16 result 18:25; 19:19; 30:8, 9; 33:16; 44:17, 21, 22, 24; 45:7, 16; 46:1, 2, 3, 5, 9, 10, 15; 57:2 results 30:10, 23; 31:14, 17; 38:19; 39:4, 9, 11, 19; 41:11, 13; 43:2, 8, 10; 46:13; 51:25; 52:2; 53:17; 54:22 retained 4:16 retrospect 44:23 reveal 55:17 review 6:19, 21; 8:7; 33:21 reviewed 8:24; 34:1; 45:13; 50:19; 57:24 Riccardo 40:25 ride 24:23 right 5:23; 6:6; 8:14; 9:14; 10:16, 20, 21; 13:3; 29:20; 35:14; 37:6; 39:25; 40:6; 42:20; 45:11; 49:3, 11; 52:13; 53:23; 55:20; 56:23; 58:10 risk 51:24 Rodriguez 8:21; 40:25, 25; 52:13; 58:6, 14 rotate 15:14 routine 17:16 rule 8:11, 20; 51:13, 17 Rules 4:3; 5:24 run 36:22</p>

<p>S</p> <p>Same 23:7; 53:1; 55:15; 57:19 sample 18:25; 19:6, 18; 20:5; 41:22 samples 27:19, 23 satisfactory 8:23 saw 44:21; 52:18; 53:7, 10; 54:24; 57:2 saying 19:4; 32:11; 35:1; 44:23; 47:13 School 30:23 screen 25:21 screening 22:20, 25; 23:12, 21; 25:8, 15, 22, 23 scriptly 35:17 se 25:22 search 48:13, 17 second 5:23; 9:12; 12:17, 20; 34:17; 38:1; 52:15; 56:19 secondary 47:18 Section 30:24 seeking 6:5; 11:5, 17 seems 14:15 selected 25:18 self-explanatory 9:25 send 19:10, 24; 20:5; 26:24; 27:18, 19; 30:10; 32:24; 33:5; 34:3 sending 27:23; 34:6 senior 22:9 sent 18:25; 19:5; 32:21; 52:11 series 17:22 serve 12:5 served 12:2 service 15:14; 52:1 services 14:17 set 26:16; 52:15 setting 25:21 settled 13:11 several 23:17; 40:18 share 35:4 sheet 31:13 short 40:8 showing 31:24 shown 46:11, 16 signs 36:4, 12; 46:11 simple 5:25 simpler 31:13 simply 24:13 Sitting 28:14 situation 49:14 situations 26:21, 22 skeletal 17:13; 47:4, 9 skirt 35:14 slightly 11:11 small 44:10 sole 33:8; 39:21</p>	<p>someone 29:13; 50:13 Sometimes 5:14, 14, 17 somewhat 17:25 somewhere 39:2 sorry 7:15; 8:15; 10:9; 15:24; 28:19; 31:10; 40:7; 43:1; 44:18; 51:14; 53:1, 23 sort 10:25; 15:9; 36:22; 48:13 speak 41:2 speaking 40:21; 41:1, 14; 44:13, 15; 49:4 special 14:21 Specialties 11:10 specialty 15:2; 18:20 species 54:20 specific 49:19 Specifically 6:21 specifics 49:20 spoke 30:5; 40:16, 18, 19, 24, 24 spoken 52:5 staff 38:12, 13 stamp 42:25 stand 28:13 standard 24:10, 12 start 40:3; 50:22 starting 57:15 state 4:10; 22:18, 22; 23:17; 25:9, 13, 16, 19 stated 47:25 statement 19:7 States 12:9 still 21:19, 20; 48:9 Stork 40:24; 52:13 Strauss 20:22; 22:8, 9, 10; 32:25; 33:5 strictly 49:23 students 15:13 studies 16:1; 17:9, 10, 11, 17; 49:21; 50:17; 52:2 study 51:3 subboards 11:9 subsequent 5:17; 24:1; 36:8, 10; 39:16 subsequently 28:22, 23 success 49:22 Suffice 50:25 sugar 17:22 suggesting 55:2 supplemental 48:9 Sure 5:11; 10:1, 10; 19:3; 28:9; 31:12; 45:23, 25; 47:7, 8; 49:16; 54:1 suspected 27:15, 17 switch 54:1 sworn 4:4 symptoms 36:4, 12 syndrome 8:10, 19; 21:7; 33:7</p>	<p>T</p> <p>talk 4:20; 30:3; 31:3; 36:22; 37:15, 16; 53:23, 25; 58:7 talking 11:25; 40:1; 55:25 tend 18:20; 29:17 terms 10:14; 18:16 test 22:6, 25; 23:12; 26:2, 11, 14, 16, 19; 27:20; 34:7; 35:15; 37:7, 24; 38:1, 2, 3; 41:22, 24; 42:2; 43:16, 21; 44:2, 7, 11; 45:15; 46:9, 10, 12, 18; 55:17; 56:18; 57:11 tested 22:23 testified 37:11 testifying 48:12 testimony 12:22; 13:4; 18:6, 21; 21:21; 24:15; 50:25 testing 18:1; 20:5; 31:20, 25; 34:3, 4, 17 tests 22:19; 25:9; 27:23; 28:2; 31:20; 36:20, 21, 22, 23, 25; 37:2; 38:7, 10, 20; 39:4, 10, 11 Therefore 6:4 Thereupon 9:19; 14:10; 26:8; 27:9; 30:17; 32:7; 58:17 thinking 31:10 Third 34:21; 38:2 though 46:19; 47:13 thought 7:15; 34:22; 42:7; 44:10, 17, 21; 48:1; 51:21 three 7:24; 28:24; 34:10; 49:25 three-page 14:11 tightened 34:11 till 57:16 times 38:25 tissues 47:16 title 20:24 today 4:17; 9:11, 13; 15:8; 28:14; 33:20; 34:2; 48:12 today's 6:18 together 21:20 told 23:9 top 42:25 total 43:10, 11, 13; 54:13, 14; 55:1 totally 37:5 toxic 47:18 training 11:3 transcript 21:22 treated 49:10, 12; 51:9 treating 5:17; 49:22 treatment 4:19; 48:2, 4, 5, 6; 50:5; 57:15 treatments 18:17</p>	<p>trouble 19:16; 45:23 truly 13:2 try 15:4; 25:7; 36:18; 50:13 trying 13:24; 24:13; 39:15; 42:15, 18; 45:10 two 5:21; 12:2; 40:12 typographical 14:22</p> <p>U</p> <p>U.S 12:17 UH 9:10; 26:24; 27:24 unaware 20:3 unborn 14:23 unclear 56:8 uncomfortable 34:6 under 18:21 understands 45:20 understood 6:3 unit 11:3; 34:13 United 12:9 University 4:13, 14; 7:12; 8:1, 4, 17; 12:21; 20:2, 10, 19; 26:1; 30:23; 35:21; 36:10, 13; 41:3; 51:8, 13, 17; 57:1 unlikely 51:21 unquote 35:20 up 22:15; 26:16; 34:11 upon 22:19; 42:4; 50:7, 25; 51:2; 57:23 urine 38:1, 2; 53:21 use 34:14, 23; 35:3 useful 19:14 using 44:2 usually 38:21</p> <p>V</p> <p>VA 42:22, 22 variable 46:25; 47:25 variables 49:15 various 50:5 versus 42:25 Veteran's 42:2, 9 Veterans 41:25; 42:7 vitae 9:15, 24; 16:25 voice 42:5 Volume 7:16, 17, 18; 8:2, 4, 12, 13, 17; 9:3, 9 Volumes 7:11, 24</p> <p>W</p> <p>wait 6:9 Wake 20:11; 22:6; 30:11, 18, 23 walk 10:25; 35:1 Washington 20:2, 10, 23; 33:1</p>	<p>way 14:7; 31:13; 34:22; 42:14; 43:20; 45:11; 46:20; 52:6 web 14:3, 4 website 14:11 week 21:13 weeks 18:23; 33:25; 50:14 Western 4:14 what's 9:24; 49:13, 14 whereas 54:14 whose 38:14 withdraw 45:9 within 15:2, 10; 43:21; 44:7; 50:13 Witmer 9:3 witness 5:13, 22; 12:2, 5, 12 wonderful 6:13 wondering 23:10 words 20:25; 41:10 work 4:12; 21:19, 20; 22:10; 38:24 worked 22:15; 32:15 working 51:15 write 38:7, 11 writing 20:21 written 39:23; 52:8 wrong 11:11 wrote 39:21; 55:22</p> <p>Y</p> <p>year 13:9 years 35:6</p> <p>Z</p> <p>ZINN 4:1, 7, 12; 9:20; 15:4; 24:14; 58:25</p>
---	--	---	--	---

CURRICULUM VITAE

January 1, 2003

Name: Arthur B. Zinn, M.D., Ph.D.

SS#: 115-40-8605

Place of Birth: Brooklyn, New York

Date of Birth: February 6, 1949

Work Address: Center for Human Genetics
University Hospitals of Cleveland
11100 Euclid Avenue
Cleveland, Ohio 44106
(216) 844-3936

Home address: 3674 Townley Road
Shaker Heights, Ohio 44122
(216) 751-4972

Education:

1965 - 1969 Brandeis University, B.A. (cum laude, chemistry)
1969 - 1976 Case Western Reserve University, M.D.
1969 - 1977 Case Western Reserve University, Ph.D. (biochemistry)
1977 - 1979 University of Minnesota Hospitals, Pediatrics residency
1979 - 1982 Yale University, Human Genetics fellowship

Professional Appointments:


Academic appointments:

1982 - 1992 Assistant Professor of Pediatrics, Case Western Reserve University
1992 - Associate Professor of Pediatrics, Case Western Reserve University
1993 - Associate Professor of Genetics, Case Western Reserve University

Hospital appointments:

1982 - Full-time member of active staff, Rainbow Babies and Childrens Hospital
of University Hospitals of Cleveland

1999 - Tod Children's Hospital, Youngstown, OH



Honors and Awards:

1969 - 1976	Medical Scientist Training Program Award
1983	Frederick C. Robbins Award, March of Dimes, Northeast Ohio chapter
1985	International Travel Award, American Society of Human Genetics
1991	Department of Pediatrics Teaching Excellence Award

Licensure:

1982 -	Ohio
--------	------

Board certification:

1981	American Board of Medical Examiners
1982	American Board of Medical Genetics (Clinical)
1996	American Board of Medical Genetics (Clinical Biochemical)

Professional Service:

Community activities:

1991 -	Medical Advisory Board, National Organic Acidemia Association
1994 -	Medical Advisory Board, Huntington Disease Society of America, Northeast Ohio Chapter

Journal reviewer:

American Journal of Human Genetics
Clinical Pediatrics
Human Molecular Genetics
Journal of Biological Chemistry
Journal of Clinical Investigation
Journal of Pediatrics
Neurology
New England Journal of Medicine

National collaborative programs:

1991 -	Register of Selected Inherited Metabolic Disorders
1991 -	Value of Bone Marrow Transplantation for Storage Disorders
1994 -	Director, Designated Gaucher Disease Treatment Center

Professional societies:

1982 -	American Society of Human Genetics
1993 -	Society for Inherited Metabolic Disorders

Study sections:

1989	NIH Special Grants Division, ad hoc review committee
1987-1989	American Heart Assn, Northeast Ohio Affiliate (ad hoc)
1989	NIH Special Grants Division, ad hoc review committee
1995	NIH Special Grants Division, ad hoc review committee

Committees:

National:

2001 -	Clinical Genetics Examination Committee, American Board of Medical Genetics
--------	---

School of Medicine:

1982	School of Medicine Task Force on Genetics
1985 - 1989	Co-coordinator, Area of Concentration in Human Genetics
1989 -	Coordinator, Area of Concentration in Human Genetics
1999 -	Committee on Students

Department:

1983	Search committee for Chief, Division of Pediatric Hematology
1994	Ad hoc committee on graduate education
1995 - 1997	Committee on Appointments and Promotion
1995 -	Coordinator, Clinical Genetics Grand Rounds

Hospital:

1986 - 1992	Co-organizer and member, Disorders of sexual development team
1987- 1994	Co-director, Center for Inherited Disorders of Energy Metabolism
1994 -	Center for Inherited Disorders of Energy Metabolism
1994 -	Director, Gaucher Disease Treatment Center
1994 -	Director, Huntington Disease Testing Center
1995 - 1997	Liver transplantation committee
1996 -	Director, Biochemical Genetics Training Program
1996 -	Laboratory Liaison Committee
1997 -	Director, Neurogenetics Clinic
1999 -	Co-Director, Metabolism Clinic

Community:

1997 -	Medical Advisory Board, Huntington Disease Society of America, NE Ohio chapter
2000 -	Ad hoc committee on newborn screening, Ohio Department of Health

Teaching Activities:

Courses:

1982 -	Human Genetics Committee (Phase 1 Medical Students), 7-10 hrs per year
1996 -	Biochemistry Committee (Phase 1 Medical Students), 2 hrs/year
1996 -	Genetics and the Law (Medical, Law and Ethics Students), 2 hrs/year
1998 -	Advanced Medical Genetics 527 (Biochemical Genetics), 32 hrs/year
2000 -	Advanced Medical Genetics 527 (Biochemical Genetics), 32 hrs/year

Postgraduate Training:

Sean Phipps, B.S.	Ph.D. Thesis Committee, 7/84 - 6/86
Vickie Zurcher, M.D.	Genetics resident, clinical training, 7/87 - 6/89
Mark Johnson, B.A.	Ph.D. Thesis committee, 7/90 - 6/96
Meral Gunay, M.D.	Genetics resident, clinical training, 7/96 - 6/99
David Everman, M.D.	Genetics resident, clinical training, 7/97 - 6/00
Derek Neilson, M.D.	Genetics resident, clinical training, 7/99 -
Mark Johnson, M.D., Ph.D.	Genetics resident, clinical training, 7/99 -
Linda Jeng, M.D., Ph.D.	Genetics resident, clinical training, 7/99 -
Khusroo Qureshi, M.D.	Genetics resident, clinical training, 7/99 - 6/01
Jeanne Brunger, B.S.	M.S. Thesis Committee member, 6/99 - 6/00
Marni Falk, M.D.	Genetics resident, clinical training, 7/00 -
Rocio Tarvin, M.D.	Genetics resident, clinical training, 7/00 -

Previous grant support:

1. A multinuclear NMR study of animal models of propionic acidemia and methylmalonic acidemia (AB Zinn, PI). Research Initiation Grant, Board of Trustees, Rainbow Babies and Childrens Hospital. Award for \$10,000 (total direct costs). July, 1983 - June, 1985.
2. Biochemical studies of defects in the electron transport chain in mitochondrial myopathies (AB Zinn, PI). Robert J. Frackelton Fund, University Hospitals of Cleveland. Award for \$10,000 (total direct costs). July, 1985 - June, 1987.
3. Complementation analysis of respiratory chain defects in patients with early-onset dementia (AB Zinn, PI). Alzheimer Center Pilot Grants, University Hospitals of Cleveland. Award of \$10,000 (total direct costs). July, 1987 - June, 1988.
4. Complementation analysis of mitochondrial cardiomyopathy (AB Zinn, PI). American Heart Association, Northeast Ohio Affiliate. Award of \$17,047 (total direct costs). July, 1987 - June, 1988.

5. Center for Disorders of Energy Metabolism (DS Kerr, Director; AB Zinn, Co-director), Rainbow Babies and Childrens Hospital Center of Care Grant. Award of \$72,280 (total direct costs). January, 1989 - December, 1991. Percent effort: 10%.
6. Center for Disorders of Energy Metabolism (DS Kerr, Director; AB Zinn, Co-director), Bureau of Maternal and Child Health. Award of \$747,112 (total direct costs). October, 1988 - October, 1993. Percent effort: 10%.
7. Ethics, Genetics, and Alzheimer Disease (Post SG, PI). NIH. Award of 155,377 (total direct costs). April, 1995 - September, 1996. Percent effort: 10%.

Current grant support:

1. Comprehensive Genetic Services in Northeastern Ohio, Ohio Department of Health #525K5 (HF Willard, PI). January 1, 2002 - December 31, 2002. Award of \$194,000 (total direct costs). Percent effort: 50%.

Publications:

Articles (peer reviewed):

1. Kosower NS, Kosower EM, Zinn AB, Carraway R. Methyl 5-diazolevulinate intervention in chemically induced porphyria of rats. *Biochem Med* 2:289-306, 1969.
2. Marshall JS, Green AM, Pensky J, Williams, Zinn AB, Carlson DM. Measurement of circulating desialylated glycoproteins and correlation with hepatocellular damage. *J Clin Invest* 54:555-562, 1974.
3. Teng TL, Harpst JA, Lee JC, Zinn AB, Carlson DM. Composition and molecular weights of butyrylcholinesterase from horse serum. *Arch Biochem Biophys* 176:71-81, 1976.
4. Zinn AB, Marshall JS, Carlson DM. Preparation of glycopeptides and oligosaccharides from thyroxine-binding globulin. *J Biol Chem* 253:6761-6767, 1978.
5. Zinn AB, Marshall JS, Carlson DM. Carbohydrate structures of thyroxine-binding globulin and their effects on hepatocyte membrane binding. *J Biol Chem* 253:6768-6773, 1978.
6. Zinn AB, Hine DB, Mahoney MJ, Tanaka K. The stable isotope dilution method: A highly accurate approach to the prenatal diagnosis of methylmalonic acidemia. *Pediatr Res* 16:740-745, 1982.
7. Phipps S, Zinn AB. Psychological response to amniocentesis: 1. Mood state and adaptation to pregnancy. *Am J Med Genet* 25:131-142, 1986.

8. Phipps S, Zinn AB. Psychological response to amniocentesis: II. Effects of coping style. *Am J Med Genet* 25:143-148, 1986.
9. Zinn AB, Kerr DS, Hoppel CL. Fumarase deficiency: A new cause of mitochondrial encephalomyopathy. *N Engl J Med* 315:469-475, 1986.
10. Olsen MM, Caldamone AA, Jackson CL, Zinn AB. Gonadoblastoma in infancy: Indications for early gonadectomy in 46,XY Gonadal Dysgenesis. *J Pediatr Surg* 23:270-272, 1988.
11. Cantrell MA, Bicknell JA, Pagon RA, Page DC, Walker DC, Saal HM, Zinn AB, Distèche CM. Molecular analysis of 46,XY females and regional assignment of a new Y-chromosome-specific probe. *Hum Genet* 83:88-92, 1989.
12. Zurcher VL, Golden WL, Zinn AB. Distal deletion of the short arm of chromosome 6. *Am J Med Genet* 35:261-265, 1990.
13. Wallis GA, Starman BJ, Zinn AB, Byers PH. Variable expression of osteogenesis imperfecta in a nuclear family is explained by somatic mosaicism for a lethal point mutation in the $\alpha 1(1)$ gene (COL1A1) of type I collagen in a parent. *Am J Hum Genet* 46:1034-1040, 1990.
14. Johnsen DC, Weissman BM, Murray GS, Zinn AB. Enamel defects: a developmental marker for hemifacial microsomia. *Am J Med Genet* 36: 444-448, 1990.
15. Rinaldo P, Welch RD, Schmidt-Sommerfeld E, Gargus JJ, Previs SF, Zinn AB. Ethylmalonic/ adipic aciduria: Effect of oral carnitine and glycine on urinary excretion of organic acids, acylcarnitines and acylglycines. *Pediatr Res* 30:216-221, 1991.
16. Coppes MJ, Liefers GJ, Higuchi M, Zinn AB, Balfe JW, Williams BRG. Inherited WT1 mutation in Denys-Drash Syndrome. *Cancer Res* 52:6125-6128, 1992.
17. Mehlman MJ, Kodish ED, Whitehouse P, Zinn AB, Sollitto S, Berger J, Chiao EJ, Dosick MS, Cassidy SB. The need for anonymous genetic counseling and testing. *Am J Hum Genet* 58:393-397, 1996.
18. Putman EA, Cho M, Zinn AB, Towbin JA, Byers PH, Milewicz DM. Delineation of the Marfan phenotype associated with mutations in exons 23-32 of the FBN1 gene. *Am J Med Genet* 62:233-242, 1996.
19. Schwartz S, Depinet TW, Leana-Cox J, Isada NB, Karson EM, Pasztor LM, Sheppard LC, Wolff DJ, Zinn AB, Zurcher VL, Zackowski JL. Sex chromosome markers: characterization using fluorescence in situ hybridization and review of the literature. *Am J Med Genet*, 71:1-7, 1997.

20. Depinet TW, Zackowski JL, Earnshaw WC, Kaffe S, Sekhon GS, Stallard R, Sullivan BA, Vance GH, Van Dyke DL, Willard HF, Zinn AB, Schwartz S. Characterization of neo-centromeres in marker chromosomes lacking detectable alpha-satellite DNA. *Hum Molec Genet* 6:1195-1204, 1997.
21. Post SG, Whitehouse PJ, Binstock RH, Bird TD, Farrer LA, Fleck LM, Gaines AD, Juengst ET, Karlinsky H, Miles S, Murray TH, Quaid KA, Relkin NR, Roses AD, St. George-Hyslop PH, Sachs GA, Steinbock B, Truschke EF, Zinn AB. The clinical introduction of genetic testing for Alzheimer Disease: an ethical perspective. *JAMA* 277:832-836, 1997.
22. DiPiero AD, Lourie EM, Berman BM, Robin NH, Zinn AB, Hostoffer RW. Recurrent immunocytopenias in two patients with DiGeorge/velocardiofacial syndrome. *J Pediatr* 131:484-486, 1997.
23. Kori AA, Robin NH, Jacobs JB, Erchul DM, Zaidat O, Remler BF, Averbuch-Heller L, Dell'Osso LF, Leigh RJ, Zinn AB. Pendular nystagmus in a peroxisomal assembly disorder. *Arch Neurol* 55:554-558, 1998.
24. Morrow MJ, Zinn AB, Tucker T, Leigh RJ. Maculopathy in spinocerebellar ataxia type 7 (NeuroImages). *Neurology* 53:244, 1999.
25. Riley D, Wiznitzer M, Schwartz S, Zinn A. A 13-year-old boy with cognitive impairment, retinoblastoma and Wilson disease, *Neurology* 57:141-3, 2001.

Thesis/Books:

1. Zinn AB. Ph.D. Dissertation, Case Western Reserve University. Studies on thyroxine-binding globulin (TBG): carbohydrate structure and liver binding, 1977.

Book Chapters:

1. Zinn AB, Plantner JJ, Carlson DM. Nature of linkages between protein core and oligosaccharides. In: *The Glycoconjugates*, Vol 1, Horowitz MI, and Pigman W (eds), Academic Press, New York, 1978, pp. 69-81.
2. Tanaka K, Zinn A, Hyman D, Hine D. Study of metabolism and prenatal diagnosis of inborn metabolic disorders using stable isotopes. In: *Mass Spectrometry in the Health and Life Sciences*, Burlingame AL, and Castagnoli N Jr (eds), Elsevier, Amsterdam, 1985, pp. 471-489.
3. Zinn AB. Genetics of sex reversal syndromes. In: *Sex reversal syndromes*, Caldamone AA (ed), *Dialogues in Pediatric Urology*, 1987, 9:2-8.


4. Zinn AB, Supinski G. Genetic diseases of the pulmonary parenchyma. In: Textbook of Pulmonary Medicine, 4th edition, Baum GL, and Wolinsky E (eds), Little, Brown, and Company, Boston, 1989, pp. 1521-1540.
5. Hoffmann G, Zinn AB. Aciduria, fumaric. In: Birth Defects Encyclopedia. The comprehensive, systematic, illustrated reference source for the diagnosis, delineation, etiology, biodynamics, occurrence, prevention, and treatment of human anomalies of clinical relevance, 2nd edition, Buyse ML (ed), Alan R Liss, Inc, New York, 1990, pp. 28-29.
6. Ruggerie D, Zinn AB. Cardiomyopathy. In: A Practical Guide to Pediatric Intensive Care, 3rd edition. Blumer JB (ed) CV Mosby, St. Louis, 1990, pp. 410-416.
7. Zinn AB. Inborn errors of metabolism. In: Neonatal-Perinatal Medicine, 5th edition, Fanaroff AA, and Martin RJ (eds), WB Saunders, Philadelphia, 1992, pp. 1118-1151.
8. Zinn AB. Genetic diseases of the pulmonary parenchyma. In: Textbook of Pulmonary Medicine, 5th edition, Baum GL, and Wolinsky E (eds), Little, Brown, and Company, Boston, 1994, pp. 1785-1816.
9. Zinn AB. Genetic disorders that mimic child abuse or sudden infant death syndrome. In: Child Abuse: Medical diagnosis and management, Reece RM (ed), Lea & Febinger, 1994, pp. 404-429.
10. Kerr DS, Zinn AB. The pyruvate dehydrogenase complex and tricarboxylic acid cycle. In: Inborn Metabolic Diseases: Diagnosis and Treatment, 2nd edition, Fernandes J, Saudubray J-M, and van den Berghe G (eds), Springer-Verlag, Berlin, 1995, pp. 110-119.
11. Zinn AB. Inborn errors of metabolism. In: Neonatal-Perinatal Medicine, 6th edition. Fanaroff AA, Martin RJ, eds, St. Louis: WB Saunders, 1997, pp. 1390-1438.
12. Post SG, Whitehouse PJ, Zinn AB. Genetics, ethics, and Alzheimer's Disease. In: Post SG, Whitehouse, eds, Genetic Testing for Alzheimer Disease: Ethical and Clinical Issues. Baltimore, MD: The Johns Hopkins Press, 1998, pp. 1-13.
13. Kerr DS, Wexler I, Zinn AB. Defects of pyruvate metabolism and the citric acid cycle. In: Inborn Metabolic Diseases, 3rd edition, Fernandes J, Saudubray J-M, van den Berghe G, eds, Springer, Berlin, 2000, **pp.** 127-138.
14. Zinn AB. Inborn errors of metabolism. In: Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant, 7th edition. Fanaroff AA, Martin RJ (eds), Mosby, St. Louis, 2001, **pp.** 1468-1516.

Invited talks/workshops/short courses:


1. Maternal PKU: A Problem Born of Success. Ohio Department of Health and Ohio Genetic Services Network, 1983.
2. Medical Genetics and Birth Defects. Northern Ohio Pediatric Society Annual Postgraduate Course (A series of eight lectures), Cleveland, 1983 (organizer and speaker).
3. Medical Genetics and Birth Defects. Northern Ohio Pediatric Society Annual Postgraduate Course (A series of four lectures), Youngstown, 1983 (organizer and speaker).
4. The role of mitochondrial disorders in neuro-ophthalmology. Neuro-Ophthalmology Update 1991, Cleveland, OH, 1991.
5. Man's 25th Chromosome: Biology and clinical disorders of the mitochondrial genome. American Academy of Pediatrics national meeting, Fall, 1991 (plenary lecture).
6. ABC's of the New Genetics. American Academy of Pediatrics national meeting, Fall, 1991 (3-hour seminar).
7. Inborn errors of fatty acid oxidation. Visiting Professor, Department of Biological Chemistry, Chicago Medical School, 1992.
8. Disorders of the mitochondrial genome. American Academy of Pediatrics national meeting, Fall, 1993 (plenary lecture).
9. ABC's of the New Genetics. American Academy of Pediatrics national meeting, Fall, 1993 (3-hour seminar).
10. Krebs cycle defects. VI International Congress of Inborn Errors of Metabolism, Troina, Italy, June 2, 1994 (plenary lecture).
11. Disorders of the mitochondrial genome. American Academy of Pediatrics CME Program, Williamsburg, VA, December 13, 1996.
12. Unstable repeat disorders: Fragile X syndrome and beyond. American Academy of Pediatrics CME Course, Williamsburg, VA, December 14, 1996.
13. Pandora's box revisited: Presymptomatic genetic testing. American Academy of Pediatrics CME Program, Williamsburg, VA, December 15, 1996.
14. Current status of genetic testing. American Academy of Pediatrics CME Course, Williamsburg, VA, December 13, 14 and 15, 1996.
15. Anonymous genetic testing. American College of Medical Genetics, Ft. Lauderdale, FL, March 2, 1997.

16. Mitochondrial diseases. Great Lakes Regional Genetics Group, Cleveland, OH, April 4, 1997.
17. Introduction to mitochondrial disease. Visiting Professor, Dept. of Medical and Molecular Genetics, Indiana University School of Medicine, Lecturer to 2nd year medical student class, and Workshop of Mitochondrial Disorders, Riley Children's Hospital, Indianapolis, IN, April 1, 1998.
18. Triplet repeat disease: Fragile X syndrome and beyond. Practical Pediatrics CME Course, American Academy of Pediatrics, St. Petersburg, FL, September 11, 1998.
19. Mitochondrial disease: The great imitator. Practical Pediatrics CME Course, American Academy of Pediatrics, St. Petersburg, FL, September 12, 1998.
20. Pandora's box revisited: Presymptomatic genetic testing of children. Practical Pediatrics CME Course, American Academy of Pediatrics, St. Petersburg, FL, September 13, 1998.
21. The changing role of molecular diagnosis in clinical practice. Practical Pediatrics CME Course, American Academy of Pediatrics, St. Petersburg, FL, September 11, 12, and 13, 1998
22. Genetic defects of the electron transport chain: A cause of myocardial dysfunction (Session co-chair: Genetic disorders of energy metabolism). Biomedical Engineering Society Annual national meeting, Cleveland, OH, October 12, 1998.
23. Nature versus nurture: Genetic determinism (Lecturer to Freshman Class Colloquium), Visiting Professor, John Carroll University, South Euclid, OH, November 6, 1998.
24. Mitochondrial genetics. United Mitochondrial Disease Foundation (Annual national meeting), Cleveland, OH, June 1, 2000.
25. Case-oriented problem solving. United Mitochondrial Disease Foundation (Annual national meeting), Cleveland, OH, June 3, 2000.
26. Mitochondrial genetics, and Thrombophilia: a complex trait. Visiting professor, Indiana University Medical School, August 23, 2000.

UH - Genetics Department Roster



Center for Human Genetics



**CLINICAL
DIRECTOR:
DIRECTOR:**

SUZANNE B. CASSIDY, MD
216-844-7236
HUNTINGTON F. WILLARD, PhD
216-368-1617

**CONSULTATION/
REFERRAL
PROCEDURE:**

For information and appointments, call 216-844-3936

**DESCRIPTION
OF SERVICES:**

The Center for Human Genetics maintains an active service focusing on clinical and laboratory diagnosis, management and genetic counseling of patients and family members for a wide range of pediatric, prenatal and adult genetic conditions. The Center also coordinates genetic counseling for individuals at risk for genetic conditions, and is actively involved in programs offered in collaboration with specialty clinics for metabolic disorders, Prader-Willi syndrome, Marfan syndrome, bone disorders, craniofacial disorders and familial cancer.

CLINICAL DIRECTOR

CASSIDY, SUZANNE B., MD O/A: 216-844-7236

Clinical Director, Center for Human Genetics, UHC

Professor of Genetics and Pediatrics, CWRU

MD-Vanderbilt University, 1976; Special Training-University of Washington (Genetics)

Board Cert.: American Board of Medical Genetics and American Board of Pediatrics

Special Interests: Prader-Willi Syndrome, Connective Tissue Disorders and Neurocutaneous Disorders

Office: UHC - Lakeside, Suite 1500

DIRECTOR

WILLARD, HUNTINGTON F., PhD O/A: 216-368-1617

Director, Center for Human Genetics, UHC

Professor of Genetics and Medicine, CWRU

PhD-Yale University, 1979

Special Interests: Molecular Cytogenetics, X Chromosome inactivation and the Genetics of X-linked Diseases

Office: UHC - Lakeside, Suite 1500

ROBIN, NATHANIEL H., MD O/A: 216-844-1612

Assistant Professor of Genetics and Pediatrics, CWRU

MD-Albert Einstein College of Medicine, 1989; Special Training-Albert

Einstein College of Medicine/Montefiore Medical Center

(Pediatrics);Childrens Hospital of Philadelphia (Genetics)

Board Cert.: American Board of Pediatrics; American Board of Medical Genetics

Special Interests: Craniofacial Genetics, Syndrome Delineation, Skeletal Dysplasias, Hearing Loss

Office: UHC-Lakeside, Suite 1500

SCHWARTZ, STUART, PhD O/A: 216-983-1134

Director of the Center for Human Genetics Laboratory, UHC

Professor of Genetics and Oncology, CWRU

PhD - University of Indiana School of Medicine, 1982; Special Training - University of Maryland (Genetics)

Board Cert.: American Board of Medical Genetics

Special Interests: Molecular Cytogenetics, Mechanisms of Chromosome Formation, Chromosomal Phenotype-Karyotype Correlations and Centromere Inactivation.

SIRKO-OSADSA, D.ALEXA, PhD O/A: 216-983-1134

Assistant Director of the Molecular Diagnostic 'Testing Laboratory, UHC

Instructor of Genetics, CWRU

PhD - University of Pittsburgh School of Medicine, 1995; Special Training - CWRU (Clinical Molecular Genetics)

Board Cert: American Board of Medical Genetics

Special Interests: Clinical Molecular Diagnostic Test Development, the Molecular Delineation of Chromosome Abnormalities, Genetic Basis of Colon Cancer susceptibility

WARMAN, MATTHEW L., MD O/A: 216-844-3936

Assistant Professor of Genetics and Pediatrics, CWRU
MD-Cornell University, 1982; Special Training-Childrens Hospital-Boston (Genetics)
Board Cert.: American Boards of Medical Genetics and Pediatrics
Special Interests: Skeletal Dysplasias, Connective Tissue Disorders
Office: UHC-Lakeside, Suite 1500


WIESNER, GEORGIA L., MD O/A: 216-844-1612
Assistant Professor of Genetics and Medicine, CWRU
MD-University of Minnesota, 1985; Special Training-University of Minnesota (Internal Medicine)
Board Cert.: American Boards of Internal Medicine and Medical Genetics
Special Interest: Cancer Genetics
Office: UHC-Lakeside, Suite 1500

ZINN, ARTHUR B., MD, PhD O/A: 216-844-5173
Associate Professor of Genetics and Pediatrics, CWRU
MD-Case Western Reserve University, 1976; Special Training-Yale University (Genetics)
PhD-Case Western Reserve University, 1977
Board Cert.: American Board of Medical Genetics
Special Interests: Unborn Errors of Metabolism, Neurological Disorders
Office: UHC-Lakeside, Suite 1500

Want to learn more? Don't forget to visit [Go Heal](#), [Go Learn](#), and [Go Discover](#)



If you have any questions regarding University Hospitals, or if you need a physician referral, please call **HealthMatch** at 1-216-795-0002 or 1-800-552-6336.



Wake Forest University School of Medicine
Department of Pediatrics / Section on Medical Genetics

Molecular Genetic Laboratory

Tel 336-716-4321 Fax 336-716-2554

Tuesday, November 7, 2000

Patient

Name..... Gwynne, Emily
Social Security #...
Date of Birth..... 10/28/99

Hospital..... Private outside doctor
Hospital Unit #.....

Sample

Laboratory Number.. 005640
Date Received..... 11/3/00
Date of Report..... 11/7/00

Type of Specimen... Blood
Test Requested..... LCHAD mutation testing

* Physicians: Gunay-Aygin, Meral, Childrens Hospital Medical Ctr, 1 Perkins Square, Akron, OH 44308

Interpretation


Analysis indicates that Emily Gwynne is homozygous for the LCHAD G1528C (Glu474Gln) mutation which accounts for 55-60% of LCHAD alleles.

Laboratory Comments

A blood sample was received from Emily Gwynne for LCHAD mutation testing. DNA was isolated by standard procedures and amplified by polymerase chain reaction. Following amplification, the product was digested with Pst I and analyzed by polyacrylamide gel electrophoresis. The G1528C mutation creates a Pst I site (a natural site occurs at bp 238 of the 270 bp product). A normal allele results in 238 and 32 bp fragments. A mutant allele results in 121, 117 and 32 bp fragments. (Reference: Ibdah JA et al., N Engl J Med 1999;340:1723-31)



Mark J. Pettenati, Ph.D., FACMG
Director, Molecular Genetics Laboratory



Wake Forest University School of Medicine*Department of Pediatrics /Section on Medical Genetics***Molecular Genetic Laboratory**

Tel 336-716-4321 Fax 336-716-2554

Tuesday, November 7, 2000

Patient

Name..... Gwynne, Eric
Social Security #...
Date of Birth..... 2/14/71

Hospital..... Private outside doctor
Hospital Unit #.....

Sample

Laboratory Number.. 005642
Date Received 11/3/00
Date of Report.. 11/7/00

Type of Specimen... Blood
'Test Requested..... LCHAD mutation testing

Physicians: Gunay-Aygin, Meral, Childrens Hospital Medical Ctr, 1 Perkins Square, Akron, OH 44308

Interpretation

Analysis indicates that Eric J. Gwynne is heterozygous for the LCHAD G1528C (Glu474Gln) mutation which accounts for 55-60% of LCHAD alleles. Genetic counseling is warranted.

Laboratory Comments

A blood sample was received from Eric J. Gwynne for LCHAD mutation testing. DNA was isolated by standard procedures and amplified by polymerase chain reaction. Following amplification, the product was digested with Psi I and analyzed by polyacrylamide gel electrophoresis. The G1528C mutation creates a Pst I site (a natural site occurs at bp 238 of the 270 bp product). A normal allele results in 238 and 32 bp fragments. A mutant allele results in 121, 117 and 32 bp fragments. (Reference: Ibdah JA et al., 1999;340:1723-31)



Mark J. Pettenati, Ph.D., FACMG
Director, Molecular Genetics Laboratory

Wake Forest University School of Medicine
Department of Pediatrics / Section on Medical Genetics

Molecular Genetic Laboratory

Tel 336-716-4321 Fax 336-716-2554

Tuesday, November 7, 2000

Patient

Name Gwynne, Kristie
Social Security #...
Date of Birth..... 5/12/64

Hospital..... Private outside doctor
Hospital Unit #.....

Sample

Laboratory Number.. 005641
Date Received..... 11/3/00
Date of Report..... 11/7/00

Type of Specimen... Blood
Test Requested..... LCHAD mutation testing

Physicians: Gunay-Aygin, Meral, Childrens Hospital Medical Ctr, 1 Perkins Square, Akron. OH 44305

Interpretation

Analysis indicates that Kristie L., Gwynne is heterozygous for the LCHAD G1528C (Glu474Gln) mutation which accounts for 55-60 % of LCHAD alleles. Genetic counseling is warranted.

Laboratory Comments

A blood sample was received from Kristie L. Gwynne for LCHAD mutation testing. ~ ~ ~ isolated by standard procedures and amplified by polymerase chain reaction. Following amplification, the product was digested with Pst I and analyzed by polyacrylamide gel electrophoresis. The G1528C mutation creates a Pst I site (a natural site occurs at bp 238 of the 270 bp product). A normal allele results in 238 and 32 bp fragments. A mutant allele results in 121, 117 and 32 bp fragments. (Reference: Ibdah JA et al., N Engl J Med 1999;340:1723-31)



Mark J. Pettenati, Ph.D., FACMG
Director, Molecular Genetics Laboratory

Patient Name: GWYNNE, EMILY MDR #: 000656953
CHEMISTRY - BLOOD Chemistry - Blood - Sendout
10/31/2000 10:00:00

Carnitine Plasma

To Do Acycarnitine if enough specimen

Acyl to DUKE

Mayo#8802

Test Name ~~~~~

Acylcarnitine, Quantitative in Plasma

Patient Results ~~~~~

In the plasma sample, elevations of several long-chain acylcarnitines were detected. The prominent accumulation of 3-OH-acylcarnitine species is consistent with a diagnosis of long chain L-3-OH acyl-CoA dehydrogenase (LCHAD) deficiency. Molecular analysis is indicated.
Performed by:

MAYO MED LABS

Patient Name: GWYNNE, EMILY MDR #: 000656953
CHEMISTRY - BLOOD Chemistry - Blood - DIAGNOSTIC
10/30/2000 09:21:00

Organic Acid Screen, U~~~~~

In this urine sample a significant pattern of hypoketotic
C6-C10 dicarboxylic aciduria and C8-C14 dicarboxylic aciduria
with prominent unsaturated aciduria. The profile is strongly
suggestive of long chain L-3-OH acyl-CoA dehydrogenase
(LCHAD) deficiency. Recommend molecular analysis.

Testing referred to Mayo Laboratories.
Interpretation ,..-----

Testing referred to Mayo Laboratories.

